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ABSTRACT
Introduction: HIV and tuberculosis (TB) coinfection, which is a major challenge for
healthcare systems worldwide, requires effective strategies to support care providers in
applying best clinical evidence in making treatment decisions about the care of individ-
ual patients. Clinical decision support (CDS) systems have the potential to facilitate the
implementation of evidence-based guidelines in clinical practice.
Aim: The aim of this thesis was to explore how a CDS system could be designed to sup-
port the adoption of evidence-based guidelines in the treatment of HIV-related TB.
Studydesign: The HIV outpatient clinic at the Karolinska University Hospital, Huddinge,
Stockholm, was the setting for a user-centered design approach structured in three phases:
contextual analysis (Studies I and II), design (Study III), and evaluation (Study IV). Study
I explores care providers’ challenges and requirements; Study II, which describes socio-
demographic and clinical characteristics of patients in this setting, analyzes the factors
associated with anti-TB treatment success as well as adverse drug reactions; Study III
proposes a CDS framework of drug therapy recommendations that is applied to HIV-
related TB treatment guidelines; Study IV formatively evaluates the conceptual design of
a CDS prototype that is based on the framework developed in Study III.
Methods: In Study I, the contextual analysis is based on observations and interviews.
Study II analyses patient treatment outcomes in the research setting between the years
1987 to 2010 (inclusive). Study III presents the design that is based on prototyping and
guideline modeling. Study IV uses focus groups of physicians and nurses in the evalua-
tion of the design.
Results: The contextual analysis revealed challenges related to the complexity of HIV-
related TB treatment (Studies I and II). Because the care providers thought they lacked
sufficient experience with HIV/TB drug therapy, they sought improved support tools and
structures (Study I). Combined HIV and TB treatment was related to treatment success,
but was also associated with adverse drug reactions (Study II). The design phase ap-
plied the eviTMA (evidence-based Treatment, Monitoring, and Assessment) framework
to model HIV-related TB treatment guidelines. This resulted in a CDS prototype that
models alternative drug therapy options, their expected effects, and recommended mon-
itoring routines (Study III). The care providers identified several potential benefits of the
eviTMA CDS prototype including support for decision making, collaboration, and qual-
ity improvement work (Study IV). Identified concerns that need to be addressed in future
include the risk of overdependence on CDS, increased workload, and aspects related to
the implementation and maintenance of a CDS system (Study IV).
Conclusions: The main contribution of this thesis is the eviTMA CDS framework de-
signed to support care providers in the adoption of evidence-based drug therapy rec-
ommendations. The framework was evaluated in a CDS prototype for HIV-related TB
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1.1.1 The burden of disease
HIV-related tuberculosis is a major challenge for global health. The World Health Or-
ganization (2013b) reports that HIV-infected individuals are about 30 times more likely
to develop active tuberculosis (TB) disease than individuals without HIV. TB is the most
common presenting illness and the leading cause of death in HIV-infected individuals.
The following global statistics are from 2012: approximately 35.3 million people had HIV;
1.1 million new cases of HIV-related TB were diagnosed; and 320,000 deaths from HIV-
related TB were recorded (World Health Organization, 2013b).
In comparison to other countries, Sweden’s number of identified cases of HIV and TB is
one of the lowest. Figures reported by the Swedish Institute for Communicable Disease
Control (2013) show that the prevalence of HIV in Sweden is less than 0.1% of the pop-
ulation. The following statistics are from 2012: approximately 6,200 patients were regis-
tered with HIV-infection; 441 cases of HIV were reported (incidence 5 cases/100,000 in-
habitants); and 645 cases of TB were reported (incidence 6.8 cases/100,000 inhabitants)
(Swedish Institute for Communicable Disease Control, 2013). However, the number of
individuals with TB has steadily increased since 2003. Surveillance data on the coin-
fection of HIV and TB are not available in Sweden because incident cases are reported
anonymously. To increase case detection of HIV-related TB, HIV testing is offered to all
patients with suspected TB disease (National Board of Health and Welfare, 2009).
1.1.2 Treatment of HIV-related TB
The treatment of HIV-related TB requires polypharmacy in which combination drug reg-
imens for both HIV and TB are used. Because antiretroviral therapy has evolved rapidly,
more than 20 antiretroviral drugs have been licensed since the emergence of the HIV
epidemic (Palmisano & Vella, 2011; Arribas & Eron, 2013).
In 1995 and 1996, when highly potent combination antiretroviral therapy (cART) was in-
troduced, an immediate reduction in morbidity and mortality due to AIDS was observed
(Palella et al., 1998). The reduction in mortality was sustained and the proportion of
AIDS-related deaths decreased (Palella et al., 2006). The introduction of cART has also
led to reduced TB morbidity (Lodi et al., 2013) and mortality (Abdool Karim et al., 2010).
HIV has become a chronic disease, which has led to new questions about the optimal
choice, timing, and duration of antiretroviral therapy (Palmisano & Vella, 2011).
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The Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents (2013)
recommends the same anti-TB treatment for HIV-infected patients and for patients with-
out HIV. These recommendations are consistent with the guidelines issued by the Euro-
pean AIDS Cinical Society (2014), as well as by the Swedish guidelines (National Board
of Health and Welfare, 2009; Referensgruppen för antiviral terapi, 2014).
1.1.2.1 Standard TB regimen
The standard treatment for drug-susceptible TB is a two-month intensive phase with
four drugs (rifampicin or rifabutin, isoniazid, pyrazinamide, and ethambutol), followed
by a four-month continuation phase with two drugs (rifampicin or rifabutin, and isoni-
azid) (Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents, 2013).
Ethambutol can be discontinued when the susceptibility to rifampicin and isoniazid has
been confirmed.
1.1.2.2 Recommended combination regimens for HIV and TB
Combined treatment for HIV and TB with cART is recommended for all HIV-infected TB
patients, although the timing of cART initiation depends on the patient’s immune sta-
tus (European AIDS Cinical Society, 2014). The two recommended ways to use cART are
the following: 1) an antiretroviral regimen based on efavirenz, which is a non-nucleoside
reverse transcriptase inhibitor (NNRTI), combined with a rifampicin-based anti-TB reg-
imen; and 2) a protease inhibitor (PI) based regimen combined with a rifabutin-based
anti-TB regimen (Panel on Opportunistic Infections in HIV-Infected Adults and Ado-
lescents, 2013; Referensgruppen för antiviral terapi, 2014). The former is preferred. If
there are no other options, the following antiretroviral drugs should be used, although
with caution: raltegravir, maraviroc, or enfuvirtid (Referensgruppen för antiviral terapi,
2014).
1.1.3 Treatment challenges
While combined treatment of HIV and TB enhances patient survival chances, there are
many challenges with this treatment.
There are overlapping drug toxicities as well as drug-drug interactions between antiretro-
viral drugs and anti-TB drugs (Arbex, de Castro Lima Varella, de Siqueira, & de Mello,
2010). The main interactions are between the anti-TB drugs rifampicin and rifabutin
and antiretroviral drugs, in particular PIs (Baciewicz, Chrisman, Finch, & Self, 2008). Pa-
tients on combined treatment have an increased risk of adverse events (Dos Santos et al.,
2013; Dean et al., 2002).
Another challenge is the risk of the immune reconstitution inflammatory syndrome (IRIS),
which is a paradoxical reaction that can result in clinical worsening of TB due to the en-
hancement of the patient’s immune response when cART is administered (Lawn, Bekker,
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& Miller, 2005). Early initiation of cART is associated with increased survival, but it has
also been shown to increase the risk of IRIS (Abdool Karim et al., 2010; Havlir et al., 2011;
Blanc et al., 2011). The optimal dosage and duration of anti-TB treatment as well as the
proper timing of cART have been identified as major unresolved questions in the treat-
ment of HIV-related TB (Khan et al., 2010).
TB relapse and drug resistance, which are mainly the result of non-adherence to treat-
ment, also pose major challenges (Aaron et al., 2004). A substantial increase in multi-
drug resistant TB (MDR-TB) and in extensively drug-resistant TB (XDR-TB) has been ob-
served in recent years (World Health Organization, 2013a).
Although several studies explore patients’ perceptions of anti-TB treatment, only a few
studies explore the perceptions of care providers (Watkins & Plant, 2005). The need to
improve our knowledge and expertise related to anti-TB treatment by care providers has
been reported in both low- and high-incidence settings (Moro et al., 2005; van der Werf,
Langendam, Huitric, & Manissero, 2012). Furthermore, some studies report variations in
adherence to HIV/TB guidelines and quality of care (Lee, Lobato, Buskin, Morse, & Costa,
2006; Chung, Chang, & Guo, 2007; Saraceni et al., 2011). Generally, we need to know
more about the challenges care providers face. Such knowledge would help us advance
the development and implementation of successful strategies to support evidence-based
care in HIV-related TB treatment.
1.2 EVIDENCE-BASED CARE
Evidence-based medicine, which emerged in the 1990s, has been defined as “the consci-
entious, explicit, and judicious use of current best evidence in making decisions about
the care of individual patients” (Sackett, Rosenberg, Gray, Haynes, & Richardson, 1996,
p. 1). It is estimated on average, there is a nine-year gap from the publication of evidence-
based medical findings in reviews, papers, and textbooks to their implementation in clin-
ical practice (Balas & Boren, 2000).
1.2.1 Clinical practice guidelines
Clinical practice guidelines (CPGs) support the dissemination of medical evidence. The
purpose is to enhance the translation of research into practice, to reduce inappropriate
practice variation, and to improve quality and safety in healthcare (Institute of Medicine
(U.S.) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines,
2011). Such guidelines were first defined as “systematically developed statements to as-
sist practitioner and patient decisions about appropriate health care for specific clinical
circumstances” (Field & Lohr, 1990, p. 38). Recently, the CPGs definition was refined to
better reflect the current emphasis on rigor, transparency, and evidence:
Clinical practice guidelines are statements that include recommendations
intended to optimize patient care that are informed by a systematic review
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of evidence and an assessment of the benefits and harms of alternative care
options. (Institute of Medicine (U.S.) Committee on Standards for Develop-
ing Trustworthy Clinical Practice Guidelines, 2011, p. 4)
Several organizations have proposed standards, for the development, quality assessment,
and implementation of guidelines. The Institute of Medicine (U.S.) Committee on Stan-
dards for Developing Trustworthy Clinical Practice Guidelines (2011) calls for transparency,
more public involvement in the development process, as well as a standard format for
presenting recommendations. The Guidelines International Network (G-I-N) proposes
a set of minimum standards for the development of high-quality and trustworthy guide-
lines (Qaseem et al., 2012). They suggest criteria for the composition of the guideline
development group and the development process, the representation of recommenda-
tions, as well as criteria for guideline appraisal, maintenance, and disclosure. The G-
I-N collaborates with the Duodecim Medical Publications Ltd, which provides concise
evidence summaries that are maintained in the Evidence-Based Medicine Guidelines
(EBMG) collection (“Duodecim Medical Publications Ltd.” 2014). Duodecim also main-
tains the Evidence-Based Medicine electronic Decision Support (EBMeDS) system, which
can be integrated with electronic health records (EHRs) and provide active guideline sup-
port through alerts and reminders (Nyberg, 2012).
A number of tools have been developed to support guideline development, appraisal,
and implementation. The Appraisal of Guidelines, Research, and Evaluation (AGREE)
Collaboration has developed the AGREE II instrument that aims to assess the quality of
guidelines and to support guidelines development, with a focus on methodological is-
sues (Brouwers et al., 2010). The Instrument for GuideLine Implementability Appraisal
(GLIA) evaluates the implementability of guidelines and identifies possible related bar-
riers (Shiffman et al., 2005). This instrument is intended for guideline developers and
for guideline users. According to Shiffman et al., implementability refers to the ease
with which guideline recommendations can be implemented. Recommendations must
clearly convey what should be done (executability) and under what conditions (decid-
ability) (Shiffman et al., 2005). One of the dimensions of the GLIA is computability,
which can be useful for evaluating implementability in a clinical decision support sys-
tem. BRIDGE-Wiz is a software tool, developed to facilitate the development of guide-
lines (Shiffman, Michel, Rosenfeld, & Davidson, 2011), that offers guideline developers
clear, transparent, and implementable recommendations. For example, by limiting the
number of verb options, guideline developers can reduce ambiguity and vagueness in
their recommendations.
1.2.2 Barriers to guideline adoption
The dissemination of high-quality CPGs does not guarantee their adoption in clinical
practice. Successful adoption of CPGs depends on how well they meet the needs and
preferences of individual users (e.g., physicians and nurses) and on the clinical context
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(Institute of Medicine (U.S.) Committee on Standards for Developing Trustworthy Clin-
ical Practice Guidelines, 2011). Grol and Grimshaw (2003) emphasize that mere dissem-
ination of recommendations is insufficient. Implementation support is needed, espe-
cially given the rapid development of new knowledge. They also report that compliance
with guidelines for acute care is generally better than for chronic care. Barriers to guide-
line adoption on the individual level, the care team level, and the organizational level
must be understood if interventions are to succeed (Grol & Grimshaw, 2003).
On the individual level, lack of knowledge and time constraints are often identified as
barriers to the adoption of CPGs in patient care (Cochrane et al., 2007; de Clercq, Blom,
Korsten, & Hasman, 2004). Cabana et al. (1999) identify various factors that pose barri-
ers to physicians’ adoption of CPGs. These are classified into factors that affect knowl-
edge, attitude, and behavior. Grimshaw, Eccles, Walker, and Thomas (2002) found that
active approaches (e.g., reminders) and multifaceted interventions are more likely to af-
fect physicians’ behavior than passive dissemination of evidence. However, they empha-
size that a better understanding of the influences on professional behavior and change
is needed. Eccles et al. (2006) suggest that intention may be a valid proxy for behavior
in the clinical setting, although the evidence is more limited than in a non-clinical set-
ting. Kortteisto, Kaila, Komulainen, Mäntyranta, and Rissanen (2010), who explored care
providers’ reasons for using CPGs, found that physicians and nurses, especially in sec-
ondary care, were more positive about CPGs than other professions.
1.2.3 Clinical decision support systems
Clinical decision support (CDS) systems are a recommended active intervention strat-
egy to facilitate the adoption of CPGs and for assistance in the delivery of safe and effec-
tive care (Institute of Medicine (U.S.) Committee on Quality of Health Care in America,
2001). Several studies have shown that reminder and alert systems can improve practi-
tioner adherence to HIV guidelines. An early example is the study by Safran et al. (1995),
which reported that computer-generated reminders and alerts increased adherence to
HIV guideline recommendations. However, no effect was noted on patient outcomes.
More recent studies have also shown improved adherence to CD4 testing (Were et al.,
2011), as well as improved patient outcomes measured by the increase in CD4 cell counts
(Robbins et al., 2012). Kitahata et al. (2003) suggest that guideline-based reminder sys-
tems may be of particular use in settings with less experienced HIV providers. Also in
TB care, adherence to screening guidelines has improved with the use of CDS systems
(Steele et al., 2005).
1.3 EFFECTIVENESS AND SUCCESS FACTORS OF CDS SYSTEMS
Reported effect measures are often provider performance (e.g., guideline adherence, or-
ganizational, or logistic process measures), and less frequently, patient outcome mea-
sures (e.g., changes in laboratory results, morbidity, or mortality). Latoszek-Berendsen,
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Tange, van den Herik, and Hasman (2010) conclude that accurate measurement of effects
on patient outcomes is difficult because of the many other factors that affect morbidity
and mortality. Therefore, measuring provider adherence to guideline recommendations
generated by a CDS system is the most direct indicator of effect. Mant (2001) describes
two advantages of process measures compared to outcome measures in the evaluation
of quality of care: 1) process measures are more sensitive to differences; and 2) process
measures are easier to interpret. However, process measures are useful only if it is as-
sumed they will produce improved outcomes.
Review studies on the effectiveness of CDS systems have shown some evidence of im-
proved provider performance (Shea, DuMouchel, & Bahamonde, 1996; Shiffman, Liaw,
Brandt, & Corb, 1999; Kawamoto, Houlihan, Balas, & Lobach, 2005; Jaspers, Smeulers,
Vermeulen, & Peute, 2011; Roshanov et al., 2011; Hemens et al., 2011; Bright et al., 2012).
Evidence of improved patient outcomes is inconsistent and understudied (Mollon et al.,
2009).
Positive effects have been reported for CDS systems that, in particular, aim to improve
treatment prescriptions/drug ordering, preventive care (e.g., vaccination), and ordering
of clinical tests (Shea et al., 1996; Bright et al., 2012; Jaspers et al., 2011). These findings
are consistent with a Health Technology Assessment (HTA) study by the Sahlgrenska Uni-
versity Hospital in Sweden (Hallin et al., 2011). This study concludes that CDS systems
lead to some improvements in guideline adherence for drug prescriptions, vaccinations,
and ordering of laboratory tests.
Damiani et al. (2010) reviewed the evidence on the effectiveness of CDS systems specifi-
cally intended to implement electronic guidelines. They conclude that CDS systems for
electronic guidelines have a positive effect on the process of care, particularly those sys-
tems that make recommendations automatically and are integrated with the clinicians’
workflow. Furthermore, they report it is a rare CDS system that makes recommenda-
tions instead of assessments. The same conclusion is applicable to affirmative feedback
and the “promotion of action, rather than inaction” (Damiani et al., 2010, p. 4). Hesel-
mans, Van de Velde, Donceel, Aertgeerts, and Ramaekers (2009) reviewed CDS systems
that implemented multidimensional guidelines, which they defined as guidelines cover-
ing several steps or aspects. They found weaker support for CDS systems compared to
the evidence from other studies. They suggested that this difference could be explained
by the explicit exclusion of simpler reminder systems that were proven more effective in
the other studies.
1.3.1 Further research needed
The evidence on the effectiveness of CDS systems as far as improving quality of care is
inconclusive. For example, while the evidence for reminder systems shows they are fre-
quently successful, the evidence for the success of active guidance systems that promote
adherence to complex clinical guidelines is less clear. Moreover, Bright et al. (2012) and
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Hemens et al. (2011) emphasize the insufficiency of evidence on the potential negative
effects of CDS systems. More data about such effects are necessary if we are to draw
reliable conclusions on the effect of CDS systems. It should also be noted that several
reviews have remarked on the lack of descriptive detail about the evaluated studies, re-
sulting in comparison difficulties (Shiffman et al., 1999; Shojania et al., 2010; Roshanov
et al., 2011). Implementation details as well as user satisfaction and effect on user work-
flow are rarely described or analyzed (Roshanov et al., 2011). Kaplan (2001) reports that
there is a preference for experimental designs to evaluate CDS systems, that focus on
quantitative measures. However, other study designs (e.g., cognitive studies, usability
testing, ethnography, and socio-technical analyses) are needed to identify and evaluate
the factors related to the successful implementation and use of CDS systems (Kaplan,
2001).
1.4 CDS SYSTEMS TO IMPLEMENT GUIDELINES
This section examines the definition of CDS systems and different methods for encod-
ing CPGs in a computable format, the so-called computer-interpretable guidelines. In
this thesis, the terms CDS and CDS system are differentiated. A definition of CDS is the
following:
Clinical decision support (CDS) refers broadly to providing clinicians or pa-
tients with clinical knowledge and patient-related information, intelligently
filtered, or presented at appropriate times, to enhance patient care. (Os-
heroff, Pifer, Teich, Sittig, & Jenders, 2005, p. x)
Hence, CDS refers to the provision of purposive, patient-specific knowledge support,
regardless of the tools used. A CDS system implies the use of computing to generate
patient-specific advice. A definition of CDS system is the following:
A clinical decision support system (CDSS) is defined as software that inte-
grates information on the characteristics of individual patients with a com-
puterized knowledge base for the purpose of generating patient-specific as-
sessments or recommendations designed to aid clinicians and/or patients in
making clinical decisions. (Institute of Medicine (U.S.) Committee on Qual-
ity of Health Care in America, 2001, p.152)
In order to generate patient-specific advice, a CDS system requires access to patient data
and a knowledge base. There are different approaches to modeling the knowledge base.
Reasoning methods may be based on mathematical modeling, pattern recognition, sta-
tistical analysis, Bayesian modeling, decision analysis, artificial neural networks, or ar-
tificial intelligence (Musen, Shahar, & Shortliffe, 2006). However, many CDS systems
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are based on simple IF-THEN-ELSE rules. Greenes (2007) states that CDS systems that
perform simple calculations to generate alerts and reminders have considerable positive
effect, while there is less evidence for diagnostic and treatment management support.
1.4.1 Computer-interpretable guidelines
Several methods have been proposed for the formal representation of computer-interpret-
able guidelines (CIGs) that can be integrated with CDS systems. By coding narrative
guidelines in a computer-interpretable format, patient-specific recommendations can
be generated and communicated at the point of clinical decision-making. The Open-
Clinical organization presents an overview of several of these methods (OpenClinical,
2002). A number of reviews and overview articles on the methods have also been pub-
lished (Wang et al., 2002; Peleg et al., 2003; de Clercq et al., 2004; Mulyar, van der Aalst,
& Peleg, 2007; de Clercq, Kaiser, & Hasman, 2008; Latoszek-Berendsen et al., 2010; Isern
& Moreno, 2008; Peleg, 2013).
The first recognized standard for the sharing of medical knowledge in modular units —
the so-called medical logic modules (MLMs) — was the Arden Syntax (Hripcsak et al.,
1990). It is a rule-based language that encapsulates individual decision rules in MLMs.
It was adopted as a standard by the American Society for Testing and Materials (ASTM)
in 1992 and is still used in many commercial systems (OpenClinical, 2002). While the
Arden Syntax has been used to encode clinical practice guidelines, it has several short-
comings that make it unsuitable for representing CIGs. For example, the Arden Syntax
does not allow shareable implementations of guidelines, its syntax rules are modular with
no control structure for modeling processes that evolve over time, and the data model is
too simplistic for current standards (Sonnenberg & Hagerty, 2006).
To address the shortcomings of the Arden Syntax, in the 1990s several research groups
developed new guideline representation models that could represent multi-step guide-
lines (Elkin et al., 2000). This research resulted in the now common Task Network Models
(TNMs), which are defined as a “hierarchical decomposition of guidelines into networks
of component tasks that unfold over time” (Peleg et al., 2003). Representations of actions
and decisions are core components of such models (Wang et al., 2002). A control-flow
language specifies the relations (e.g., sequential links and branching) between compo-
nents. An expression language is needed to describe eligibility and decision criteria. Fi-
nally, a guideline execution engine is needed to generate patient-specific recommenda-
tions (Latoszek-Berendsen et al., 2010).
Two TNM formalisms that have been used in CDS systems for HIV care are EON (Musen,
Tu, Das, & Shahar, 1996) and PROforma (Fox et al., 1997). The EON formalism was used
to model the T-HELPER system for AIDS and HIV-related care (Musen, Carlson, Fagan,
Deresinski, & Shortliffe, 1992). The system consisted of an electronic patient record, a
therapy-planning component, an eligibility assessment component, and a clinical trial
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protocol knowledge base (Musen et al., 2006, p. 599). The T-HELPER system would in-
dicate if a patient was eligible for a clinical trial protocol. If the patient was enrolled, the
system would recommend the needed therapy.
The PROforma formalism was used in the RetroGram system to provide antiretroviral
therapy advice based on HIV–1 genotype information (Fox, Patkar, & Thomson, 2006).
A randomized controlled trial showed that genotypic testing with interpretation support
by the RetroGram system led to improved virological outcomes (Tural et al., 2002). How-
ever, the relative contribution of this CDS system to the improved outcomes could not
be determined.
In an effort to facilitate standardization, six predominant formalisms (Asbru, EON, GLIF,
GUIDE, PRODIGY, and PROforma) were systematically compared (Peleg et al., 2003).
The structural organization of guidelines was similar in most of the formalisms. How-
ever, the computational models used in these formalisms varied considerably, and the
different models varied in scope. The comparison study concluded that while it was not
feasible to set a standard, individual components could be standardized and shared. The
focus on model standardization has shifted to sharing of CIG knowledge, which is still an
important research topic (Peleg, 2013).
Only a few CIG methods have been implemented in clinical settings (Isern & Moreno,
2008; Gooch & Roudsari, 2011). The TNM-based formalisms have been criticized for their
lack of flexibility (Grando, Glasspool, & Boxwala, 2012). Shalom et al. (2008) noted that
CIG methods are typically demonstrated using disease guidelines with a well-defined
clinical pathway. The clinical trial protocols in the T-HELPER system are an example of
this. However, in some settings, the rigid workflow structuring and task sequencing may
hinder the work of care providers (Patkar & Fox, 2008).
1.5 INTERACTION DESIGN OF CDS SYSTEMS
Interaction design, as this term is used here, refers to the interaction between the user
and the CDS system. Musen et al. (2006) describe two characteristics that relate to the
interaction design: 1) the mode used to offer the advice; and 2) the communication style.
CDS systems can be described as active or passive, depending on the way in which advice
is offered. The communication style can be either critiquing or consulting.
1.5.1 Mode by which advice is offered (active or passive)
A CDS system may offer advice in an active or passive mode (Musen et al., 2006). An
active system, which is automatically initiated by events or time triggers, does not re-
quire any user effort (Greenes, 2007). Alert and reminder systems are examples of active
systems that may help prevent unintentional medical errors (Tamblyn et al., 2008). A
disadvantage of such systems is that they may also cause workflow disruptions and alert
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fatigue. In order to avoid alert fatigue, thresholds for alerts and reminders should be cal-
ibrated (Bates et al., 2003). A passive system, on the other hand, is triggered by the user.
Its advantage is that the user, rather than the system, decides on the advice and its imple-
mentation. The disadvantage is that, before actively initiating the system, the user must
be aware of the need for support.
Automatic (i.e., active) CDS systems have been shown to be more effective than on-demand
(i.e., passive) CDS systems (van Wyk et al., 2008). However, these findings are not con-
sistent. Reminders may not always lead to expected improvement of practitioner per-
formance (Kortteisto et al., 2014). In their review study, Hemens et al. (2011) found no
association between automatic provision of decision support and CDS system success.
1.5.2 Communication style (critiquing or consulting)
A CDS system may use a critiquing or a consulting communication style (Musen et al.,
2006). The critiquing style agrees with provider decisions or suggests alternative deci-
sions. In simple patient cases, this style is effective in issuing alerts and reminders. How-
ever, there is also a need for CDS in more complex cases, such as patients with multiple
medications or chronic conditions (Sittig, Krall, Dykstra, Russell, & Chin, 2006; Bright
et al., 2012). In such cases, the consulting style may be more useful as a support for com-
plex decision-making because it is more specific and more flexible (Bouaud, Séroussi,
Falcoff, & Venot, 2006). The consulting style generates advice on, for example, diagnoses
or treatments that are based on patient-specific characteristics, and, in some cases, other
user data (Musen et al., 2006). The critiquing style has had greater effect on patient out-
comes than the consulting style (Sintchenko, Magrabi, & Tipper, 2007).
1.6 ACCEPTANCE AND USE OF CDS SYSTEMS
Kortteisto, Komulainen, Mäkelä, Kunnamo, and Kaila (2012) describe the perceived use-
fulness of CDS systems as a decisive factor affecting system use. Kilsdonk, Peute, Kni-
jnenburg, and Jaspers (2011) have found that the most frequently reported influential
factors on system use among physicians are their expectations and beliefs about CDS
systems. Physicians are more willing to use such systems if they can use and control
them efficiently.
Kushniruk (2001) has found that physicians’ reasoning processes and patterns, when
making diagnoses or prescribing treatment plans, may be greatly influenced by the way
in which information is organized and presented in computer interfaces. Therefore, dif-
ferent strategies of information processing and decision-making should be considered
both in the design and in the evaluation of computer-based systems.
The five rights model states that CDS systems should convey the following: 1) the right
information, 2) to the right person, 3) in the right intervention format, 4) through the
right channel, 5) at the right time in the workflow (R. Campbell, 2013, original emphasis).
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Specifically, researchers emphasize that CDS systems should require minimal user effort,
should be delivered at the time of decision-making, and should be integrated with the
user’s workflow (Kawamoto et al., 2005; Bates et al., 2003; James, 2002).
1.6.1 User-centered design
Studies have shown that the design of CDS systems using a user-centered approach may
increase the usability of CPGs (Verhoeven, Steehouder, Hendrix, & Van Gemert-Pijnen,
2010; Kilsdonk, Peute, Riezebos, Kremer, & Jaspers, 2013). J. Iivari and N. Iivari (2011)
describe user-centeredness as a composition of user focus, work-centeredness, user in-
volvement, and system personalization. According to Gulliksen et al. (2003), user partici-
pation is a key criterion for successful IT development. They describe 12 key principles of
user-centered system design that cover the analysis, design, evaluation, construction and
implementation phases. Users should participate in these phases that take into account
user needs, goals, and work domains. Simple design representations, such as mockups
and prototypes, should be developed in an iterative process to visualize and evaluate the
design ideas. All phases should focus on usability, which is defined as “the extent to which
a product can be used by specified users to achieve specified goals with effectiveness, ef-
ficiency, and satisfaction in a specified context of use” (International Organization for
Standardization, 2010). Hence, the usability of an artifact depends on the experience of
individual users in a context.

2 AIM AND OBJECTIVES
The aim of this thesis was to explore how a clinical decision support (CDS) system could
be designed to support the adoption of evidence-based guidelines in the treatment of
HIV-related TB. The thesis covers three phases: (1) contextual analysis, (2) design, and
(3) evaluation. The specific objectives of the four studies in this thesis are stated below:
1. Contextual analysis
• To explore the challenges faced by nurses and physicians in the treatment of
HIV-related TB, with a major focus on identifying opportunities for informa-
tion and communication technology. (Study I)
• To describe socio-demographic and clinical characteristics of patients with
HIV-related TB in a Swedish cohort, and to identify factors associated with
success in anti-TB treatment and with adverse reactions to anti-TB treatment.
(Study II)
2. Design
• To design a CDS prototype to support care providers in the adoption of guide-
lines for HIV-related TB treatment. The CDS prototype includes 1) a knowl-
edge base model of drug therapy guidelines, and 2) a graphic user interface
for care providers. (Study III)
3. Evaluation
• To evaluate the conceptual design of a CDS prototype for treatment guidelines
for HIV-related TB. (Study IV)
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3 OVERVIEW OF THE THESIS
The four studies in this thesis deal with different phases of a user-centered approach to
designing a CDS prototype that aims to promote evidence-based care in the treatment
of HIV-related TB. A graphic overview of the individual studies is presented in Figure 3.1.
The first phase, consisting of two studies, is a contextual analysis of the setting: Study
I explores the challenges and needs experienced by care providers with different levels
of expertise and experience in the treatment of HIV-related TB; Study II describes socio-
demographic and clinical characteristics of patients in this setting and analyzes patient
outcome data. The knowledge acquired in these two studies was used to inform the de-
sign and evaluation phases, which also consist of two studies: Study III proposes a CDS
framework for drug therapy recommendations that is applied to HIV-related TB guide-
lines by designing a CDS prototype; Study IV formatively evaluates the CDS prototype by
exploring care providers’ perceptions of its conceptual design.
Study I: 
Exploration of clinicians’ 
perceptions of challenges 
Study IV: 
Evaluation of the 
conceptual design of the 
CDS prototype 
Study III: 




Description of patient 
characteristics, treatment, 
and outcome data 
Qualitative study design 
Quantitative study design 
Modeling & prototyping Qualitative study design 




FIGURE 3.1: Overview of the thesis. The square boxes represent the individual studies in the




A multi-strategy design was used to explore challenges of HIV-related TB treatment from
a qualitative perspective (Study I) and from a quantitative perspective (Study II), and to
design and formatively evaluate a CDS framework and prototype (Studies III and IV).
This chapter is structured as follows: section 4.1 describes the study setting; section 4.2
presents an overview of the research participants; section 4.3 and section 4.4 describe
the overall study design, data collection, and analytical methods used in the individual
studies; section 4.5 describes ethical considerations. A summary overview of the details
of the individual studies is presented in Table 4.1.
4.1 SETTING
The HIV outpatient clinic at the Karolinska University Hospital, Stockholm, was chosen
as the setting for this thesis. The clinic’s size was one reason for choosing this setting. It
is the largest HIV outpatient clinic in Sweden (Svedhem, 2013). At the time of writing,
the clinic cares for about 1,800 of the 6,200 HIV-infected patients in Sweden. The staff
consists of physicians, nurses, counselors, and secretaries. Staff and patient numbers for
2010 and 2013 (years of data collection for Studies I and IV) are presented in Table 4.2.
A second reason for choosing this setting was that one member of the research team is
employed at the hospital as a Senior Consultant in Infectious Diseases. This placement
gave the team full access to the research setting.
TABLE 4.2: Patients and staff at
the HIV outpatient clinic.
Year
2010 2013
Approx. no of patients 1600 1800
No. of physicians 16 13
No. of nurses 13 11
Karolinska University Hospital is the largest of seven university hospitals in the six medi-
cal care regions in Sweden (Anell, Glenngård, & Merkur, 2012). The hospital is owned by
the Stockholm County Council and was established by a merger between the Karolinska
Hospital and the Huddinge University Hospital in 2004 (Karolinska University Hospital,
2005). There are two major centers: Karolinska Solna in the north of Stockholm, and
Karolinska Huddinge in the south of Stockholm. The Infectious Diseases Department
has TB wards at both centers and an HIV outpatient clinic at Karolinska Huddinge.
There are 290 municipalities and 20 county councils in Sweden (Swedish Association of
Local Authorities and Regions, 2009). Stockholm County Council is the largest council,















































































































































































































































































































































































































































































































































































































































































































































































































































The county councils are responsible for the funding and provision of health care (Anell
et al., 2012). The Swedish National Board of Health and Welfare provides national guide-
lines for the allocation of resources in Health and Medical Care and Social Care (National
Board of Health and Welfare, 2014a).
All cases of suspected or confirmed HIV or TB disease must be reported to The Public
Health Agency of Sweden and The County Medical Officer. These cases are also subject to
mandatory contact tracing (National Board of Health and Welfare, 2014b). The Swedish
Communicable Diseases Act regulates this reporting (SFS 2004:168, 2004). The Act also
requires that such treatment be provided at no charge to patients. Because some of the
drugs are very expensive, HIV/AIDS treatment is covered by a system of reallocation of
funds among the county councils (Anell et al., 2012).
4.1.1 Organization of care at the HIV outpatient clinic
All patients at the HIV outpatient clinic have a designated care team that consists of a
physician, a nurse, and a counselor. The planning of care is the shared responsibility
of the care team. Physicians are medically responsible for patients, and nurses are re-
sponsible for monitoring treatment and administering drugs. Counselors support and
motivate patients as well as conduct the HIV contact tracing. As the counselors have no
responsibility for the drug therapy, this thesis does not examine their role in patient care.
The focus of this thesis is specifically on the tasks performed by physicians and nurses in
the treatment of patients with HIV-related TB.
4.1.1.1 Treatment of HIV-related TB
The treatment of HIV-related TB is the responsibility of the HIV outpatient clinic. The
treatment and the tasks performed by physicians and nurses are illustrated in Figure 4.1.
Diagnosis Some patients may have severe immunosuppression when they are diag-
nosed with TB. This is typically the case with patients whose HIV-infection has not been
previously diagnosed. It is routine to offer to test patients for HIV when TB is suspected.
Therefore, some patients are simultaneously faced with two severe diagnoses, both with
complicated drug regimens. For patients who are on an antiretroviral drug regimen when
TB is diagnosed, anti-TB drugs are administered taking into consideration the possible
drug-drug interactions. For patients who are not in antiretroviral therapy when they are
diagnosed with TB, treatment is initiated with only anti-TB drugs for the first couple of
weeks. Depending on the patient’s immune status, antiretroviral therapy may be intro-
duced after 2 to 8 weeks.
Treatment and monitoring If patients are very ill or if there is a risk of contamination,
anti-TB treatment is initiated at the inpatient clinic. After discharge, patients continue
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their treatment at the HIV outpatient clinic. The anti-TB treatment lasts for at least six
months (a 2-month initiation phase followed by a 4-month continuation phase).
During the initiation phase of two months, patients see nurses for weekly or bi-weekly
visits where their drugs are administered and monitored. Physician visits are scheduled
after four weeks and after two months. During the continuation phase of about four
months, patients have monthly follow-up visits with nurses. Physician appointments are
less frequent (about bi-monthly); the recommended schedule for both nurse and physi-
cian appointments may vary depending on patient needs.
Physicians who have specialized in TB treatment are only involved if their assistance is
requested. However, at the time of this research, the HIV outpatient clinic did not have
access to all the monitoring equipment that was needed for TB follow-up. Therefore,
nurses at the TB outpatient clinic assisted with ophthalmology controls. TB contact trac-
ing was also performed at the TB outpatient clinic.
Weeks 0 1 2 4 8 12 16 20 24 
Weeks 0 1 2 4 8 12 16 20 24 
•  Assess effects & tackle 
complications  
•  Renew/modify prescriptions  
•  Discuss treatment with patient 
•  Take tests & dispense drugs  
•  Assess adherence & complications 
•  Motivate patient  
•  Schedule follow-up 
•  Ophthalmology control  
•  Contact Investigation  
•  Decide treatment strategy   
•  Prescribe drugs & monitoring  
•  Discuss coinfection with patient   
•  File report with Swedish Institute 
for Communicable Disease 
Control 
•  (Take tests) & dispense drugs  
•  Discuss treatment, drug 
administration, side-effects  












Weeks 4, 8 
HIV PHYSICIAN HIV NURSE TB NURSE 
•  Ophthalmology control   
•  Take tests  & dispense drugs  
•  Assess adherence & complications 
•  Motivate patient  





FIGURE 4.1: The treatment process of HIV-related TB disease. The vertically oriented pro-
cess on the left illustrates the overall tuberculosis treatment process from start to end. The
three horizontally oriented processes represent the patient’s path at treatment initiation and
monitoring & follow-up appointments. The week numbers indicate when the care visits are
planned (treatment initiation = week 0). The tasks of physicians and nurses are outlined in
the shaded boxes.
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Follow-up Treatment success is evaluated six to twelve months after treatment com-
pletion.
4.1.2 Swedish national guidelines
In 2009, a guidance document was published with the stated purpose of increasing knowl-
edge about TB and providing uniform guidelines for treatment and care (National Board
of Health and Welfare, 2009).
National recommendations for antiretroviral therapy of HIV-infection have been pub-
lished and revised regularly since 2002 by the Swedish Reference Group for Antiviral Ther-
apy (RAV) and the Medical Products Agency (Public Health Agency of Sweden, 2014).
The most recently revised version was published in 2013 (Referensgruppen för antiviral
terapi, 2014).
4.1.3 Technical context
Sweden is a leading country in its use of information and communication technology
(ICT) in healthcare. All counties in Sweden use an EHR system for the clinical docu-
mentation of care (Jerlvall & Pehrsson, 2013). TakeCare (CGM, CompuGroup Medical)
is the most widely used EHR system in Sweden, with about 37,000 users (Profdoc Care
AB, 2014b). The Karolinska University Hospital has used TakeCare since the merger in
2004 and in 2008 it was decided to implement it throughout Stockholm County Council
(Profdoc Care AB, 2014a).
InfCare HIV is a national quality registry for all Swedish HIV clinics. The registry is also
used as a tool for CDS and (tele-)consultations at the point of care (Rosén, 2010). The
CDS module graphically visualizes clinical data from several sources. Individual patients’
drug therapy over time, HIV viral load, and CD4 cell counts are displayed in one graph,
giving care providers a good overview of the progress of patient treatment. Additionally,
the graph displays HIV-resistance and drug concentrations (Sönnerborg, 2007). The
graph is used for (tele-)consultations with other care providers, for consultation meet-
ings, and for discussions with patients. InfCare HIV can be accessed from the EHR sys-
tem, but there is no integration of clinical data between the two systems. The laboratory
parameters for the graph display are accessed directly from the clinical laboratory. How-
ever, each patient’s drug therapy information must be registered manually.
4.2 OVERVIEW OF THE STUDY PARTICIPANTS
Physicians and nurses were selected for participation in Studies I, III, and IV because
they share the main responsibility in the HIV/TB drug therapy. Purposeful sampling was
used to identify participants for the studies (Patton, 2002). Most participants practiced
at the HIV outpatient clinic where patients with HIV-related TB are treated. However,
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most physicians did not practice full-time at the HIV outpatient clinic. Furthermore,
some TB specialists were also involved because of their medical expertise. Altogether, 13
nurses and 9 physicians participated in one or more of the four studies in this thesis, as
illustrated in Table 4.3.
TABLE 4.3: Study participants in Studies I,III, and IV.
Participation
ID Role Infectious Diseases Unit Study I Study III Study IV
N01 RN HIV outpatient clinic x xa x
N02 RN HIV outpatient clinic xa xa x
N03 RN HIV outpatient clinic x x x
N04 RN HIV outpatient clinic x x
N05 RN HIV outpatient clinic x x
N06 RN TB clinic x
N07 RN TB clinic x
N08 RN HIV outpatient clinic x
N09 RN HIV outpatient clinic x x
N10 RN HIV outpatient clinic x
N11 RN HIV outpatient clinic x
N12 RNc HIV outpatient clinic x
N13 LPNc HIV outpatient clinic x
P01 MD HIV outpatient clinic x x
P02 MD TB clinic x x
P03 MD TB clinic x x
P04 MDb HIV outpatient clinic x
P05 MDb HIV outpatient clinic x
P06 MD HIV outpatient clinic x
P07 MD HIV outpatient clinic x
P08 MD HIV outpatient clinic x
P09 MD HIV outpatient clinic x
a Informal participation. b Resident. c Research profile. Abbreviations:
RN, registered nurse. MD, medical doctor. LPN, licensed practical nurse.
4.3 CONTEXTUAL ANALYSIS
Studies I and II identify and describe the challenges in HIV/TB care where CDS might be
useful.
4.3.1 Study I - Qualitative contextual analysis
4.3.1.1 Study design
A qualitative research approach based on cognitive task analysis (CTA) was used to ex-
plore the challenges that care providers face in managing HIV-related TB. Qualitative re-
search methods are appropriate when the research purpose is to explore “people’s ex-
periences, perceptions, opinions, feelings, and knowledge” (Patton, 2002, p. 4). CTA is
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a specific qualitative approach that can be used to explore and explain the mental pro-
cesses that are involved in performing a task, such as clinical decision-making among
care providers in the studied context (Klein & Militello, 2001). Multiple data collection
methods are often used in combination (Crandall, Klein, & Hoffman, 2006, p. 15). In this
study, observations and interviews were used to identify challenging tasks and to explore
the perceptions of care providers related to their decision-making and work routines.
Field observations were made at the HIV outpatient clinic so the author could acquaint
herself with the clinical setting and the care providers’ workflow. Observations allow the
researcher to gain a deeper insight into a research context, which is essential for a holis-
tic perspective (Patton, 2002). The insights acquired by observations can support the
analysis of other data sources, such as interviews (Patton, 2002).
The interviews, which were conducted with physicians and nurses, allowed the author
to expand on her observations of external behavior and to explore more deeply the in-
terviewees’ perceived challenges (Patton, 2002, p.306). Two different semi-structured
interview techniques were selected: the task diagram interview and the critical decision
method (CDM).
The task diagram interview is a technique that was developed for Applied Cognitive Task
Analysis (ACTA), which is a streamlined method of CTA (Militello & Hutton, 1998). The
purpose of this type of interview, which is conducted with subject matter experts, is to
gain a surface-level overview of a task and to identify elements that are cognitively chal-
lenging. The findings are captured in a task diagram that guides future in-depth inter-
views. In this study, task diagrams of clinical tasks in the treatment process of HIV-related
TB were mapped. CDM-inspired interviews were then conducted that further explored
the challenges in the identified tasks.
The CDM is an in-depth interview technique that is suitable for gathering “informa-
tion about cognitive functions such as decision-making and planning and sensemaking
within a specific challenging incident” (Crandall et al., 2006, p. 73). The interview con-
cerns a retrospective narrative of a non-routine event in which the interviewee, who is
an expert in the studied field, has played a key role. The CDM is conducted in four so-
called sweeps (Crandall et al., 2006, p. 73ff): in the first sweep, an incident is selected; in
the second sweep, key events are plotted on a time line; in the third sweep, probes are
used to explore the cognitive functions and processes of key events; and in the fourth
sweep, “what if” questions are asked to identify expert-novice differences. In this study,
the CDM interview was used to explore care providers’ perceptions of their general chal-
lenges encountered in treatment planning and decision-making. The approach is re-
ferred to as CDM-inspired because the narrow focus on single incidents gradually shifted
to a broader focus on experienced challenges in general.
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4.3.1.2 Data collection and analysis
Sampling strategy Participants were selected based on their expertise (HIV or TB) and
experience (e.g., specialist/resident). Variations in these dimensions were sought. Snow-
ball sampling was used to identify additional participants (Patton, 2002). Subject matter
experts for the task diagram interview were identified for the two specialties (HIV and
TB) and the two professional roles (physician and nurse) – i.e., four participants in total.
In the CDM-inspired interviews, the majority of the participants were selected from the
HIV outpatient clinic where patients with HIV-related TB are treated. Four physicians
(1 HIV specialist, 1 TB specialist, and 2 residents at the HIV outpatient clinic) and five
nurses (4 HIV nurses, and 1 TB research nurse) participated (Table 4.3).
Data collection During one week, on-site observations at the HIV outpatient clinic were
made, and informal discussions with the clinic’s physicians, nurses, and counselors were
conducted. The author’s purpose with these observations and discussions was to be-
come acquainted with the clinical setting and the work routines. The aim was to learn
the following: how the organizational and technical systems work; how care providers
interact and collaborate; which documents and information resources are used; who the
potential subject matter experts for subsequent interviews are; which tasks seem to re-
quire tacit knowledge; and which tasks seem to be cognitively challenging. Physicians
and nurses were observed before, during, and after patient encounters. Also, one of the
weekly consultation meetings among the physicians was observed.
The author, who conducted the interviews, used an interview guide to make sure all rel-
evant themes were addressed (Appendix Study I). Separate interview guides were used
for the task diagram interviews and the CDM-inspired interviews. In the former, care
providers were asked to reflect on the major steps they took prior to, during, and after
patient encounters. They were also asked to identify which tasks were most cognitively
challenging. Task diagrams were developed as mind-maps. All interviewees in the CDM-
inspired interviews were shown a task diagram and were asked to describe an event in
which they had to make a decision involving one or more of the previously identified
challenging tasks. All interviews were audio recorded and lasted for approximately 30
minutes to 2 hours. The CDM-inspired interviews were generally longer.
Data analysis Hand-written notes from the observations and the informal discussions
described the treatment process of HIV-related TB. The interviews, which were conducted
in Swedish, were transcribed verbatim and then analyzed using inductive thematic anal-
ysis (Braun & Clarke, 2006). The individual steps of the analysis are detailed in Figure 4.2.
The qualitative data analysis program Nvivo (Version 9; QSR International, Doncaster,
VIC, Australia) was used to code and categorize the data. Although the interview tran-
scripts were in Swedish, English code and category labels were used to facilitate the re-
porting of findings. Illustrative interviewee comments were translated into English and
presented as quotes.
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Steps of the thematic analysis
1. Familiarizing with the text
Interviews were transcribed verbatim (in Swedish) and
read through several times to immerse in the text.
2. Generating initial codes
Two researchers independently coded portions of the transcripts,
which were then compared and discussed. After agreement on
a coding strategy, the coding of challenging tasks and relat-
ing factors was completed by the principal researcher (CW).
3. Searching for themes
Candidate themes were identified in a process of group-
ing codes into thematic categories and subcategories.
4. Reviewing themes
Categories were revised and regrouped in discussion among co-authors.
This involved going back and forth between the text and codes.
5. Defining and naming themes
In the final step of analysis, the definition and naming of all thematic
categories and sub-categories was discussed critically among co-authors.
6. Producing the report
All themes were described and discussed in relation to the re-
search question. Representative quotes were used for illustration.
FIGURE 4.2: Individual steps of the thematic analysis of interview transcripts in Study I, based
on the process described by Braun and Clarke (2006).
4.3.2 Study II - Quantitative contextual analysis
4.3.2.1 Study design
This study used a quantitative retrospective design for the data from 1987 to 2010 to de-
scribe the context of HIV-related TB care. Because a highly effective combination ther-
apy for HIV (cART) was introduced in 1996, the study population was stratified into two
groups, hereafter referred to as cohorts: the early cohort (1987 to 1995, before the intro-
duction of cART) and the late cohort (1996 to 2010, after the introduction of cART). Socio-
demographic and clinical characteristics of patients were described and compared for
the two cohorts. In the late cohort, cART was evaluated as a possible predictor of anti-TB
treatment success and of adverse reactions. Anti-TB treatment success was classified as
successful if patients completed treatment without any registered TB recurrence within
the follow-up period until the end of 2011. Adverse reactions were defined as severe nox-
ious or unintended responses to the anti-TB treatment that resulted in a (temporary)
discontinuation or modification of the treatment.
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4.3.2.2 Data collection and analysis
Inclusion criteria The following inclusion criteria were specified: adult patients (≥18
years at the time of the TB diagnosis), HIV-infection and TB disease in the study period,
diagnosis and treatment in the Stockholm County Council. Of the 189 identified patients,
62 patients were excluded as explained in Figure 4.3. Thus, the total study population









a) Not treated in Stockholm County
Council (n=40)
b) No verified TB diagnosis (n=4)
c) Diagnosed with TB >1 month be-
fore HIV diagnosis (n=2)
d) Duplicate records (n=9)




Diagnosed with TB before the introduc-
tion of cART in 1996
Late cohort (n=101):
Diagnosed with TB after the introduction
of cART in 1996
FIGURE 4.3: Study population and stratification, Study II.
Data collection Primary data for HIV-infected patients who were treated for TB disease
in the Stockholm County Council from January 1987 to December 2010 were collected
from medical records. Secondary data were collected from the InfCare HIV quality reg-
istry and archival records. Data were first recorded manually on paper records. There-
after, the data were transferred to an electronic database management system.
Statistical analysis Descriptive statistics were used to analyze socio-demographic and
clinical data. The median and the interquartile range (IQR) was presented for numeric
variables. Percentages were presented for categorical variables. Comparisons between
the two cohorts were made using the Mann-Whitney U-test for continuous variables
when the distribution deviated from normality. A chi-square test was also used, or, where
appropriate, Fisher’s exact test for categorical variables was used. The level of statistical
significance was specified at 5%.
Multivariate logistic regression analyses were performed in the late cohort to evaluate
the influence of cART on anti-TB treatment success and adverse reactions. Reference
values for all variables were coded as 0. In the analysis of treatment success, the pre-
dictor variable cART was coded as a dichotomous variable (cART=1, no cART=0). The
following control variables were included in the analysis: sex (female=1, male=0), age in
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years (≤37=1,>37=0; 37 was the median age in the cohort), and CD4 counts (cells/µL) at
the time of TB diagnosis (>200=1,≤200=0). In the analysis of adverse reactions, the pre-
dictor variable cART was coded as a three-leveled variable (before TB-diagnosis=1, after
TB-diagnosis=2, no cART=0). The same control variables were included, but CD4 counts
(cells/µL) were coded the opposite way (≤200=1,>200=0). The reason was that poor im-
mune status (CD4 count≤200 cells/µL) was expected to have a possible negative associ-
ation with treatment success, and a possible positive association with adverse reactions.
Univariate logistic regression analyses were performed to determine the crude associ-
ation of all independent (predictor) variables with the dependent (outcome) variables.
Multicollinearity between independent variables was determined based on the variance
inflation factor (VIF). The threshold for multicollinearity was set at VIF >4. Goodness-
of-fit was examined using the Hosmer and Lemeshow test.
4.4 DESIGN AND FORMATIVE EVALUATION OF A CDS PROTOTYPE
Studies III and IV address the design and formative evaluation of a CDS prototype that
can be used to deal with some of the challenges that were identified in the contextual
analysis.
4.4.1 The eviTMA framework
Clinical practice guidelines (CPGs) guide physicians in their decision-making for treat-
ment and follow-up. Additional knowledge is needed to assess the potential benefits
and harms of different options: knowledge about indications and contra-indications
of drugs, interactions between drugs, and (known) intended and unintended effects of
drugs.
Because the purpose of a drug therapy is to improve or maintain a health condition, the
patient’s response to treatment must be monitored continuously to assess the progress
that will inform decisions about future steps (e.g., whether to continue, modify, or stop
a drug therapy). This thesis proposes the eviTMA (evidence-based Treatment, Monitor-
ing, and Assessment) framework to model evidence-based drug therapy recommenda-
tions. The choice of treatment informs monitoring activities. Monitoring results enable
assessment of treatment progress. Assessment then informs future treatment decisions.












FIGURE 4.4: Conceptual model of the eviTMA (evidence-based Treatment, Monitoring, and
Assessment) framework. The arrows between the circles represent relationships. The choice
of treatment informs monitoring activities. Monitoring results enable assessment of treat-
ment progress. Assessments then inform future treatment decisions.
4.4.2 Study III - Design
4.4.2.1 Study design
A user-centered approach was used to design a CDS prototype for HIV-related TB drug
therapy recommendations, based on the eviTMA framework. Norman and Draper (1986,
p. 61), who coined the term user-centred design, emphasized that “[t]he needs of the
users should dominate the design of the interface, and the needs of the interface should
dominate the design of the rest of the system”. In this study, prototyping and the Unified
Modeling Language (UML) were used in combination.
Prototyping was used to design the graphic user interface (GUI), or front-end, of the CDS
prototype (visible to end-users). It is a recommended technique that creates a common
understanding between users (e.g., physicians and nurses) and designers (Gulliksen et
al., 2003). In this study, the design was informed by the challenges identified in the con-
textual analysis (Studies I and II). It was formatively improved by discussing evolving ver-
sions of the GUI prototype with the care providers.
The UML was used to design and describe a knowledge base model of drug therapy
guidelines, or back-end, of the CDS prototype (not visible to end-users). The UML is a
standardized pictorial (symbolic) language that is used within the field of systems devel-
opment to formalize systems analysis and design by models (Kimmel, 2005). A system’s
structure and interaction with users can be represented by different types of diagrams.
Class diagrams are diagram types that can be used to describe the static structure of a
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system in terms of objects and their attributes, operations, and relationships (Bruegge &
Dutoit, 2009, p. 77). In this study, the UML class diagram was used to describe a knowl-
edge base model of drug therapy guidelines for HIV-related TB treatment.
4.4.2.2 Design procedure
Sampling strategy Study participants – some of whom had previously been involved in
the project and some who had not – were invited to provide feedback on evolving versions
of the GUI prototype. Two physicians and two nurses participated. One physician and
one nurse had participated previously; the others were new to the project (Table 4.3).
Prototyping The GUI prototype was created using Microsoft® PowerPoint®, which is a
widely available and much used tool. While the tool is not specifically intended for GUI
design, its functionalities were acceptable for the purpose of this study.
The research team developed initial design sketches. The team discussed these sketches
informally with some care providers at the HIV outpatient clinic (see informal partici-
pation, Table 4.3). When the GUI prototype achieved a sufficient level of functionality
and content specification, the study participants were invited to offer feedback on the
design in formal one-to-one discussion meetings. The author presented the prototype
using a fictitious patient case scenario and a discussion guide (Appendix Study III). The
discussion guide was designed to elicit the participants’ views on the functionality and
content of the prototype, as well as their ideas on on how the envisioned CDS system
could be integrated with the clinical workflow. The author took notes during the discus-
sion and compiled summaries that were sent to the study participants individually for
their review.
Knowledge base modeling using UML The knowledge sources used consisted of CPGs
issued by national and international authorities (Panel on Opportunistic Infections in
HIV-Infected Adults and Adolescents, 2013; Referensgruppen för antiviral terapi, 2014;
National Board of Health and Welfare, 2009), clinical protocols at the HIV outpatient
clinic, and the summary of product characteristics (SPCs) of anti-TB drugs as described
in FASS (The Swedish Medicines Information Engine) (“FASS,” 2014). The documents
were examined for treatment, monitoring, and assessment recommendations. Concepts
and relationships were extracted and modeled in a UML class diagram, which repre-
sented the knowledge base model. The class diagram was iteratively refined during the
development process.
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4.4.3 Study IV - Formative evaluation
4.4.3.1 Study design
A qualitative approach based on user-centered evaluation was used to formatively eval-
uate a functional version of the CDS prototype proposed in Study III. User-centered eval-
uation (UCE) can verify the quality of a product, detect problems, and support decisions
(van Velsen, van der Geest, Klaassen, & Steehouder, 2008; De Jong & Schellens, 1997). In
this study, the purpose was mainly to gain knowledge about prospective end-users’ per-
ceptions of the conceptual design of the CDS prototype and to detect usability concerns
that might help to improve its design and inform future implementation. The CDS pro-
totype was demonstrated to care providers and evaluated using focus groups. The Uni-
fied Theory of Acceptance and Use of Technology (UTAUT) (Venkatesh, Morris, Davis, &
Davis, 2003) was applied as an analytical framework.
Focus groups were held with the physicians and nurses at the HIV outpatient clinic. A
focus group is “an open-ended group discussion which the researcher guides, typically
extending over at least an hour, possibly two or more” (Robson, 2011, p. 294). In user-
centered evaluation studies, focus groups are suitable for acquiring an understanding of
the attitudes, behaviors, and intentions of users (van Velsen et al., 2008). In this study,
the conceptual design and usability of the demonstrated CDS prototype were the foci of
the evaluation.
The UTAUT was applied as an analytical framework because it is an evaluated model that
has been shown to explain 70% of the variance in the intention with using technology
(Venkatesh et al., 2003). According to the UTAUT, intentional behavior in using technol-
ogy is determined by performance expectancy, effort expectancy, and social influence. The
intentional behavior, combined with facilitating conditions, determines the actual use of
the technology (Figure 4.5). In this study, the UTAUT was used to develop the interview
guide for the focus groups and to analyze the focus group transcripts.
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Voluntariness Gender Age Experience ou s of Use 
- -ue .Rseac oe 
significant role as direct determinants of user 
acceptance and usage behavior: performance 
expectancy, effort expectancy, social influence, 
and facilitating conditions. As will be explained 
below, attitude toward using technology, self- 
efficacy, and anxiety are theorized not to be direct 
determinants of intention. The labels used for the 
constructs describe the essence of the construct 
and are meant to be independent of any particular 
theoretical perspective. In the remainder of this 
section, we define each of the determinants, 
specify the role of key moderators (gender, age, 
voluntariness, and experience), and provide the 
theoretical justification for the hypotheses. 
Figure 3 presents the research model. 
Performance Expectancy 
Performance expectancy is defined as the degree 
to which an individual believes that using the sys- 
tem will help him or her to attain gains in job 
performance. The five constructs from the dif- 
ferent models that pertain to performance 
expectancy are perceived usefulness (TAM/TAM2 
and C-TAM-TPB), extrinsic motivation (MM), job-fit 
(MPCU), relative advantage (IDT), and outcome 
expectations (SCT). Even as these constructs 
evolved in the literature, some authors acknowl- 
edged their similarities: usefulness and extrinsic 
motivation (Davis et al. 1989, 1992), usefulness 
and job-fit (Thompson et al. 1991 ), usefulness and 
relative advantage (Davis et al. 1989; Moore and 
Benbasat 1991; Plouffe et al. 2001), usefulness 
and outcome expectations (Compeau and Higgins 
1995b; Davis et al. 1989), and job-fit and outcome 
expectations (Compeau and Higgins 1995b). 
The performance expectancy construct within 
each individual model (Table 9) is the strongest 
predictor of intention and remains significant at all 
points of measurement in both voluntary and man- 
datory settings (Tables 5, 6, and 7), consistent 
with previous model tests (Agarwal and Prasad 
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FIGURE 4.5: Unified Theory of Acceptance and Use of Technology (UTAUT) model adopted
from (Venkatesh, Morris, Davis, & Davis, 2003). Copyright c© 2003, Regents of the University
of Minnesota. Used with permission.
4.4.3.2 Data collection and analysis
Sampling s rategy Twelve purposefully selected physicians (with specialties in HIV or
TB treatment) and all the eleven nurses at the HIV outpatient clinic were invited to par-
ticipate in the formative evaluation study. The enue for the physician focus group was
a lunch session on a weekday when the physicians ad regularly scheduled consulta-
tion meetings. Despite the researchers’ effort in finding a suitable time and place for the
meeting, only four of twelve physicians attended. The nurses were invited to participate
in a separate s ssion. Their focus g oup was held at one of their education meetings
where ten of the eleven nurses attended.
Data collection An interview guide was developed that covered the following themes:
content and functionality, usability (perceived usefulness and perceived ease of use), in-
fluence on work practices, and acceptance (Appendix Study IV). The themes and ques-
tions we e bas d on the UTAUT model and the findings from Study I. A function l version
of the eviTMA prototype proposed in Study III was d veloped using Justinmind Proto-
typer Pro software (version 5.6.0, Justinmind, San Francisco, USA).
The author gave a brief presentation to the focus groups in which the background and
purpose of the project were explained. This presentation was followed by a demonstra-
tion of the CDS prototype. Two facilitators (not research team members) conducted the
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focus group discussions. They were familiar with the project and had participated in de-
veloping the interview guide. The primary facilitator led the discussion and determined
that all topics were covered. The assistant facilitator helped maintain the focus on the
topics and tracked the time. Screenprints of the CDS prototype were available in printed
form to support the discussion. The author, who participated in both focus groups as
an observer, was available to answer questions about the functionality of the prototype.
The focus groups lasted for approximately 1 hour and were audio recorded.
Data analysis As in Study I, thematic analysis was used for the qualitative data analysis
(Braun & Clarke, 2006). The author transcribed (in Swedish) the focus group discussions
verbatim. Three researchers were actively involved in the data analysis. The researchers
read the transcripts several times to immerse themselves in the material. Unlike the anal-
ysis in Study I, both deductive and inductive approaches were used to abstract and cat-
egorize the data.
In the deductive phase, a coding scheme was defined for the four UTAUT constructs,
which are defined below (Venkatesh et al., 2003, p. 447ff):
• Performance expectancy is defined as “the degree to which an individual believes
that using the system will help him or her to attain gains in job performance”.
• Effort expectancy is defined as “the degree of ease associated with the use of the
system”.
• Social influence is defined as “the degree to which an individual perceives that im-
portant others believe he or she should use the new system”.
• Facilitating conditions are defined as “the degree to which an individual believes
that an organizational and technical infrastructure exists to support use of the sys-
tem”.
Two researchers, working independently, coded the transcripts. An inter-rater reliability
comparison was made to evaluate the coding consistency, which was substantial (Co-
hen’s kappa coefficient, 0.68). Disagreements were resolved in discussions with the third
researcher before proceeding with the inductive analysis.
In the inductive phase, the author recoded the transcripts using open coding. The pur-
pose was to identify potential benefits and concerns. Within each UTAUT construct,
meaning units were identified and labeled with a descriptive code. The codes were grouped
in categories. The three researchers discussed and developed themes and sub-themes.
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4.5 ETHICAL CONSIDERATIONS
Ethical approval for the four studies was obtained from the Research Ethics Committee
at Karolinska Institutet: Studies I, III, IV (case number 2010/238–31/4); Study II (case
numbers 2006/1445–31/2 and amendment 2012/155–32). The participants in Studies I,
III, and IV gave their written consent to participate in the research project. They were in-
formed verbally and in writing about the purpose of the research and how the data would
be analyzed and reported. The interviews and focus groups were audio recorded. Audio
files were stored safely at multiple locations. During transcription, the names of the in-
terviewees as well as names of others mentioned in the interviews were replaced with
unique codes to ensure confidentiality during analysis. The identity of the participants
was not revealed in the presentation of the findings. The data collected and analyzed
in Study II was stored in a database management system. Personal identifiers (names or
personal identification numbers) of patients were stored separately in a remote location.
All analyses were conducted and reported on a group level. Consent was not required of
the patients in the study.

5 FINDINGS
This chapter is structured as follows: section 5.1 describes the identified challenges from
the contextual analysis (Studies I and II); section 5.2 describes the design and formative
evaluation of a CDS prototype for drug therapy guidelines for HIV-related TB treatment
(Studies III and IV).
5.1 CONTEXTUAL ANALYSIS
5.1.1 Study I
HIV and tuberculosis coinfection: A qualitative study of treatment challenges faced by care
providers.
The aim of this study was to understand challenges faced by nurses (n = 7) and physi-
cians (n = 6) in the treatment of patients with HIV-related and TB disease.
The researchers identified the following five challenges based on analysis of the inter-
views:
1. Complexity inherent to HIV/TB co-treatment. The care providers reported that the
concomitant treatment of HIV/TB coinfection is complex. Their main difficulties
occur in diagnosing TB and in choosing a treatment strategy. The choice of treat-
ment strategy depends on the patient’s condition and drug regimen. It is essential
to avoid drug-drug interactions between antiretroviral drugs and anti-TB drugs.
Adverse drug reactions, which are common, often require treatment modifications.
2. Clinical knowledge and task standardization. The care providers lacked confidence
in their clinical knowledge and experience with HIV-related TB treatment. They
thought the clinical practice guidelines provided only limited support. They were
also concerned about the lack of task standardization. The care providers said
they wanted computer-based guideline support although some of them were con-
cerned about the potential risks of such support.
3. Care coordination and collaboration. The uncertainty about the division of respon-
sibilities created problems with care coordination and collaboration. Because of
the occasional unavailability of staff, it was sometimes difficult to have access to ex-
pertise. The care providers also said the communication and collaboration among
care team members and between the HIV and TB clinics should be improved.
4. Information management. The information systems did not provide optimal infor-
mation management. Insufficient structure, overview, and information access in
the EHR can create a high cognitive workload and can mean additional time and
effort are required. The care providers thought these problems could be alleviated
by the use of automatic reminders.
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5. Engaging patients in their treatment. Because the complex treatment is arduous
for patients, it was difficult for the care providers to engage patients (using moti-
vating discussions) in their prescribed treatment. Language and cultural barriers
contributed to this difficulty. The care providers wanted improved routines for dis-
cussing treatments with patients.
The following comment points to the importance of continuous assessment and re-evalu-
ation of treatment decisions and plans:
. . . Because it is somewhat disturbing if you have your treatment plan and
then suddenly ‘Well, no, now this doesn’t apply anymore. Now there is a liver
side effect. Then we have to start over from the beginning.’ So that is also part
of the whole process when some patients don’t follow this train that just rolls
on; it is also a part of the treatment that we have these problem situations
that sometimes require quite a bit of thinking. (Physician)
In my opinion, the ‘train that just rolls on’ is a mechanical and inflexible metaphor for
patient treatment. It captures the rigidity of care protocols formulated only as a set of
discrete treatment options. In reality, complex patient treatment is sometimes unpre-
dictable – treatment does not always follow a permanent track. In the research reported
on in this thesis, I often reflected on this railway metaphor. Even when treatment guide-
lines seem inflexible, care providers should have space to use their judgment in real world
settings. The issue is whether it is possible to design a CDS system that recommends spe-
cific workflow routines and yet still allows for flexibility in their adoption.
5.1.2 Study II
Tuberculosis among HIV-infected patients in Stockholm, Sweden, 1987–2010: treatment
outcomes and adverse reactions.
The aim of this study was to describe HIV-related TB treatment in the studied context by
taking a quantitative perspective on a population of patients diagnosed with and treated
for HIV-related TB disease in the Stockholm County Council from 1987 to 2010.
5.1.2.1 The study population
The number of patients in the study population was N = 127: 26 patients were in the early
cohort and 101 patients were in the late cohort. Twenty-nine countries were represented
by the patient group. The majority of the patients were born outside Sweden, mainly in
Sub-Saharan African countries (85% in the early cohort and 88% in the late cohort). The
percentage of female patients was 23% (n = 6) in the early cohort and 49% (n = 49) in the
late cohort (p = 0.02). Figure 5.1 is a bar chart, split by geographic origin, of the annual
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number of cases during the study’s timeframe. The patients’ median age was similar in



























FIGURE 5.1: Bar chart of HIV/TB coinfection cases 1987–2010 (N = 127), split by geographic
origin. The dotted vertical line represents the stratification of the study population into two
cohorts, the early cohort (1987–1995, n = 26) and the late cohort (1996–2010, n = 101). Figure
used with permission from the publisher (Study II).
5.1.2.2 Anti-TB treatment outcomes
The successful anti-TB treatment outcomes for patients increased from 65% (n = 17) in
the early cohort to 91% (n = 92) in the late cohort (p = 0.002). This change is evidence of
the improved treatment in the late cohort when cART was available. In the late cohort of
patients, 31% (n = 31) were on cART at the time of the TB diagnosis, 45% (n = 45) initiated
cART at a median of 1.9 months (IQR 0.9–3.9) after TB diagnosis, and 25% (n = 25) had
no concomitant cART. Adverse reactions leading to treatment modifications occurred in
23% (n = 23) of patients in the late cohort; of these patients, 96% (n = 22) were on con-
comitant cART. Liver side effects (n = 8) were the most frequent manifestation of adverse
reactions. The median duration of successful anti-TB treatment, excluding patients with
TB in the central nervous system, was 8 months in the early cohort and in the late cohort.
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5.1.2.3 Predictors of anti-TB treatment success and adverse reactions
The influence of cART in anti-TB treatment, including the occurrence of adverse reac-
tions, was analyzed in 99 of the 101 patients in the late cohort (two patients whose treat-
ment outcomes could not be evaluated were excluded). The results of the multivariable
logistic regression analyses are presented in Table 5.1. Treatment success was associated
with cART and a CD4 cell count >200 cells/µL. The initiation of cART after the TB diag-
nosis was positively associated with adverse reactions.
TABLE 5.1: Results of the logistic regression analyses in Study II: factors related to
treatment success and adverse reactions to anti–TB treatment for patients with
HIV-related TB, diagnosed 1996 or later (N=99). Table used with permission from
the publisher (Study II).
Successful treatment outcomes (N = 99)
Yes (n = 92) No (n = 7) Univariate Multivariate
Variables n (%) n (%) OR (95% CI) OR (95% CI)
cART
Yes 72 (78) 3 (43) 4.8 (1.0–23.2) 13.3 (1.5–114.8)a
No 20 (22) 4 (57) Reference
Sex
Female 47 (51) 1 (14) 6.3 (0.7–54.1) 5.9 (0.5–71.1)
Male 45 (49) 6 (86) Reference
Age, y
≤ 37 57 (62) 1 (14) 9.8 (1.1–84.6)a 9.8 (0.9–105.0)
> 37 35 (38) 6 (86) Reference
CD4 count, cells/µL
≤ 200 51 (55) 6 (86) Reference
> 200 41 (45) 1 (14) 4.8 (0.6–41.7) 17.2 (1.2–236.6)a
Adverse reactions to anti–TB treatment (N = 99)
Yes (n = 23) No (n = 76) Univariate Multivariate
Variables n (%) n (%) OR (95% CI) OR (95% CI)
cART
Before TB diagnosis 3 (13) 27 (36) 2.6 (0.2–26.3) 2.8 (0.3–29.3)
After TB diagnosis 19 (83) 26 (34) 16.8 (2.1–135.6)b 13.3 (1.6–112.4)a
No cART 1 (4) 23 (30) Reference
Sex
Female 13 (57) 35 (46) 1.5 (0.6–3.9) 1.0 (0.3–3.0)
Male 10 (44) 41 (54) Reference
Age, y
≤ 37 18 (78) 40 (53) 3.2 (1.1–9.6)a 2.7 (0.8–9.0)
> 37 5 (22) 36 (47) Reference
CD4 count, cells/µL
≤ 200 18 (78) 39 (51) 3.4 (1.2–10.1)a 1.8 (0.5–6.2)
> 200 5 (22) 37 (47) Reference
a p < 0.05. b p < 0.01. Abbreviations: cART, combined antiretroviral therapy. OR, odds ratio.
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5.2 DESIGN AND FORMATIVE EVALUATION OF A CDS PROTOTYPE
5.2.1 Study III
Modeling evidence-based drug therapies: the eviTMA clinical decision support framework
applied to HIV/TB care.
The aim of this study was to design a CDS prototype to support care providers in the
adoption of guidelines for HIV-related TB treatment.
5.2.1.1 Knowledge base model
The knowledge base model described below is a structural representation of drug therapy
guidelines for the treatment of HIV-related TB that is based on the eviTMA framework.
The model is represented as a UML class diagram (Figure 5.2).
The class diagram is organized into three packages: TMA_Recommendations, Drugs,
Tests. The TMA_Recommendations package contains the concepts and relationships
to represent drug therapy guidelines. The Drugs package represents a drug repository.
Individual drugs are described with their intended and unintended effects, as well as in-
teractions with other drugs. The Testspackage represents a test repository with defined
order sets.
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FIGURE 5.2: UML class diagram of the eviTMA knowledge base model of drug therapy
guidelines for HIV-related TB treatment. The model is organized into three packages:
TMA_Recommendations, Drugs, Tests. The classes represent guideline concepts and
medical domain knowledge.
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The concepts of the eviTMA model are described below:
TreatmentGroup Specifies the eligibility criteria for a subset of drug therapy recom-
mendations. An example of aTreatmentGroupwould be Extrapulmonary TB with
involvement of the central nervous system. The drug therapy recommendations that
belong to this TreatmentGroup apply to patients who meet the eligibility criteria.
TreatmentPhase Specifies a distinct treatment phase. Anti-TB treatment starts with an
intensive phase of two months. If the treatment goal of this phase is achieved, the
continuation phase can be initiated. Hence, the intensive phase is a prerequisite
for the continuation phase.
Regimen Specifies a recommended drug regimen and its evidence rating — for exam-
ple, Rifampin-based anti-TB therapy combined with an efavirenz-based antiretro-
viral therapy (Evidence rating AII). The Regimen is composed of Drugs, which are
retrieved from the Drug repository. Intended and adverse effects of the Regimen
are represented by the associated classes IntendedEffect and AdverseEffect.
Recommended protocols for drug administration and monitoring are represented
by the associated classes DrugAdministrationProtocol and MonitoringPro-
tocol.
DrugAdministrationProtocol Specifies a drug administration and dosage schedule
for a Regimen. For example, during the intensive phase daily therapy is recom-
mended. The protocol consists of AdministrationEvents that specify the ad-
ministration time intervals.
MonitoringProtocol Specifies a monitoring schedule for a Regimen. It consists of
MonitoringEvents.
MonitoringEvent Specifies the time interval for a monitoring event. Further, the Mon-
itoringEvent is associated with the class Test.
Test Specifies a test that should be performed at a MonitoringEvent. A test can be a
procedure (e.g., vision control). It can also be a blood test (e.g., a liver function test).
The latter is composed of OrderSets (e.g. liver transaminases).
OrderSet Specifies theBiomarkers that should be tested. For example, a liver transam-
inasesOrderSet is composed of the liver enzymes aminotransferase (AST) and ala-
nine aminotransferase (ALT).
AssessmentCondition This is an association class between the classes Monitoring-
Protocol and Effect. Its purpose is to define conditions for assessing monitor-
ing results. It specifies a logic expression and recommends an action if the expres-
sion evaluates as true. For example, an AST test result >5 times the upper limit
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of normal may indicate a drug-induced liver injury (Panel on Opportunistic In-
fections in HIV-Infected Adults and Adolescents, 2013). Hence, an alert should be
issued to notify care providers that an adverse drug reaction is suspected.
DrugRisk This is an association class between the classesDrug andAdverseEffect. It
specifies the estimated risk interval of an adverse effect. For example, hepatobiliary
disorders are common (>1% and<10%) for the anti-TB drug isoniazid (FASS, 2002),
but uncommon (>0.1% and < 1%) for the anti-TB drug rifabutin (FASS, 2008).
RegimenRisk Like DrugRisk, but the association is between the classes Regimen and
AdverseEffect.
5.2.1.2 GUI prototype
A screenprint of the GUI prototype is presented in Figure 5.3.
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FIGURE 5.3: Graphic user interface (GUI) mockup of the eviTMA CDS prototype for HIV-
related TB. The GUI consists of four main components: overview, graph, drug therapy rec-
ommendations, drug therapy protocols.
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The GUI prototype has four components:
1. The overview component contains a summary of patient characteristics and infor-
mation about the treatment. A message field lists all issued alerts and reminders
(e.g., lab results that should be examined).
2. The graph component depicts a graphic treatment overview. Laboratory parame-
ters, drug therapy, and event markers for qualitative examinations and results are
graphed on a timeline.
3. The drug therapy recommendations component is the core CDS component. Drug
therapy recommendations are presented in a panel with three tabs (treatment, mon-
itoring, assessment).
4. The drug therapy protocols component depicts the recommended drug adminis-
tration and monitoring protocols. These are only shown if a drug therapy has been
chosen for the patient.
The drug therapy recommendations component is the only interactive part of the CDS
prototype. The following sections describe its sub-components: treatment, monitoring,
and assessment.
Treatment The Treatment sub-component is intended mainly for physicians (Figure 5.4).
The physician follows a five-step process when deciding on a treatment strategy (1. se-
lection of treatment group, 2. selection of treatment phase, 3. choice of drug regimen, 4.
choice of drug administration protocol, and 5. choice of monitoring protocol). In each
step, the physician is presented with all potentially applicable options that are contained
in the guideline model. A static recommendation layer presents guideline content, in-
dependent of patient characteristics. Alternative treatment options are presented in a
tree-view structure, ordered by quality of evidence and strength of recommendations.
The tree-view allows the user to browse guideline content. The dynamic recommen-
dation layer provides patient-specific recommendations by annotating non-supported
treatment options with a warning symbol.
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FIGURE 5.4: Graphic user interface mockup of treatment recommendations, which is in-
tended mainly for physicians. The drug therapy options, ordered by quality of evidence and
strength of recommendations, represent the guideline content independent of patient char-
acteristics (i.e., static recommendation layer). The warning icons illustrate patient-specific
recommendations (i.e., the dynamic recommendation layer).
Monitoring The Monitoring sub-component is intended mainly for nurses (Figure 5.5).
Drug administration and monitoring protocols become available after the physician has
saved a drug therapy choice to file. In the Monitoring component, detailed monitoring
checklists can be accessed for each recommended monitoring event.
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FIGURE 5.5: Graphic user interface mockup of monitoring recommendations, which is in-
tended mainly for nurses. A monitoring protocol with recommended monitoring events for
the duration of the drug regimen is presented. The user selects a monitoring event in the pro-
tocol by moving the horizontal slider. A list of recommended monitoring tests is presented in
a tree-view. The user can browse information related to the individual tests and biomarkers.
Assessment The Assessment sub-component is intended for both nurses and physicians
(Figure 5.6). It provides support for adverse drug reactions (ADRs). An ADR-browser lets
the user explore relationships between drugs and ADRs. Furthermore, alerts are shown
if an ADR is suspected based on monitoring results.
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FIGURE 5.6: Graphic user interface mockup of assessment recommendations, which is in-
tended for nurses and physicians. The user can explore relationships between drugs and
adverse drug reactions (ADRs) that could potentially occur, based on available pharmacovig-
ilance data. The warning icons represent alerts, which appear if an ADR is suspected based
on monitoring results.
5.2.2 Study IV
Qualitative evaluation of the eviTMA clinical decision support model applied to HIV/TB
care.
The aim of this study was to evaluate the conceptual design of the CDS prototype that
resulted from Study III with physicians (n = 4) and nurses (n = 10) at the HIV outpatient
clinic.
Based on the demonstration, all care providers said they intended to use the CDS pro-
totype. In the following sections, the principal benefits and concerns identified in the
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analysis are presented for the four UTAUT constructs of performance expectancy, effort
expectancy, social influence, and facilitating conditions. Each construct is introduced
with a representative comment from the focus groups.
5.2.2.1 Performance expectancy
Off hand, I would say that I would get a better feeling of what I do- and an
overview of the patients, especially when we take over each other’s patients.
(Physician)
The study participants identified several potential benefits of the eviTMA CDS proto-
type that could lead to improvements in job performance. Generally, they thought that
the prototype contributed to a better overview of their patients’ treatments. They also
thought this would improve control of treatments. The following specific uses were iden-
tified: support in patient involvement and education, educational support for care provi-
ders, collaboration support, and support for quality improvement work.
The care providers perceived that visualization of treatment progress, as well as protocols
and checklists, were CDS features that could improve their performance. Treatment rec-
ommendations and alerts, as well as the adverse drug reaction feature, produced mixed
opinions. Mainly, the care providers were concerned about possible overdependence on
the CDS system (i.e., the concern that the users of the prospective CDS system would not
think independently). They emphasized that the recommendations should not be too
rigid or too steering. On the other hand, they viewed alerts (e.g., in the case of inappro-
priate medication) as a potential benefit. The only feature not considered beneficial was
the opportunity to read and write user comments in the CDS (e.g., to comment about a
treatment decision or an alert)1. One reason was that this functionality would conflict
with the use and purpose of the EHR system.
5.2.2.2 Effort expectancy
Nurse: The advantage is if you are new at a workplace, it is very simple to just
click on this.
Facilitator: Tell us more.
Nurse: If I were completely new and I didn’t know so much about TB treat-
ment, like – what should be done now? It is so simple – now I can see which
tests I should perform, which drugs the patients should receive. It is simple
to just step in.
1The commenting functionality was not in CDS mockups that resulted from Study III. It was added as
an additional feature in the functional prototype in Study IV
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Because the care providers did not have the opportunity to test the prototype in a hands-
on situation, they were not able to express any strong opinions about its ease of use.
However, based on what they had seen, they thought it appeared easy to use.
They thought that the visualization of treatment progress contributed to a better overview,
which could reduce the time needed for information searches. They appreciated having
all the information they needed in one place. On the other hand, they emphasized that
too much functionality or information in the system might create cluttering (e.g., the
commenting functionality). The care providers also noted that their active use of the
CDS system would increase their workload, due to the additional data entry required.
5.2.2.3 Social influence
[. . . ] the key is to convince the physicians. (Nurse)
Social influence is defined as “the degree to which an individual perceives that impor-
tant others believe he or she should use the new system” (Venkatesh et al., 2003). The
researchers did not identify this type of social influence in their analysis. However, they
did identify a type of professional dependency. Nurses were concerned that the success
of the system depended on the attitudes and behavior of the physicians.
5.2.2.4 Facilitating conditions
It takes quite a long time for experts to agree on this document [clinical prac-
tice guideline] that should be written in present time – there is a constant
reevaluation of what is optimal. (Physician)
As the above comment illustrates, the issue of knowledge management and maintenance
was discussed. The care providers revealed concerns about this issue. Different providers
and organizations may have different routines and opinions about best practice recom-
mendations. Furthermore, such recommendations may change rapidly. Someone must
update the system, which takes time and requires financial resources.
A main concern of the care providers was the integration of the CDS system with the
EHR system. If not well integrated, the addition of a new system could also contribute to
substantial increase in administrative workload and potential inconsistencies between
systems. Another concern related to the legal requirements of the documentation and
the use of data.
6 DISCUSSION
This thesis proposed eviTMA as a CDS framework for modeling treatment, monitoring,
and assessment recommendations for evidence-based drug therapies in HIV-related TB
care. The framework supports adherence to recommended workflow routines while still
allowing for flexibility in their adoption. A user-centered approach was used to exam-
ine the challenges that care providers face in treating HIV-related TB (Studies I and II),
to design a CDS prototype that addresses these challenges (Study III), and to formatively
evaluate the CDS prototype (Study IV). The four studies were conducted at the HIV out-
patient clinic at the Karolinska University Hospital, Huddinge, in Stockholm. In Studies
I, III, and IV, physicians and nurses at the hospital informed and formatively evaluated
design sketches and the CDS prototype.
6.1 CHALLENGES AND NEEDS IN HIV/TB CARE
6.1.1 HIV-related TB in the study setting
This thesis showed that TB among HIV-infected individuals in Stockholm County Coun-
cil is strongly linked to migration from highly endemic countries (Study II), which is gen-
erally the case in northwestern EU countries (Pimpin et al., 2011). A previous study has
shown that the majority of AIDS cases in Sweden are ‘late testers’ (i.e., the time interval
between the HIV and AIDS diagnosis is ≤3 months). Immigrants represent the largest,
increasing proportion of these patients (Brännström, Akerlund, Arneborn, Blaxhult, &
Giesecke, 2005). The group of late testers poses medical challenges because immuno-
suppression is associated with higher mortality (Palella et al., 2003).
In the study setting (the late cohort, years 1996 to 2010), the majority of patients were im-
munosuppressed (CD4 cell count<200 cells/µL) and not on antiretroviral therapy when
diagnosed with TB (Study II). The initiation of a combined cART and anti-TB treatment
was associated with successful treatment outcomes, which was defined as a success-
fully completed treatment without any registered TB recurrence within at least one year’s
follow-up. However, adverse reactions to anti-TB treatment (including IRIS) were com-
mon, especially among those who initiated cART following their TB diagnosis, which is
consistent with previous research (Blanc et al., 2011). In the current Swedish national
guidelines for HIV treatment, PI-based cART is a recommended first-line alternative af-
ter the NNRTI efavirenz, in combination with anti-TB treatment (Referensgruppen för
antiviral terapi, 2014). The most common cART in the study setting was PI-based, which
has been associated with a higher risk of adverse reactions than efavirenz-based cART
(Dos Santos et al., 2013).
The above findings indicate that HIV-related TB care in the study setting is complex, and




6.1.2 Clinical practice guidelines (awareness and adherence)
The care providers in this thesis faced challenges that arose because of gaps in clinical
knowledge, guidelines with limited usefulness, and a lack of task standardization (Study
I). The low number of yearly reported cases of HIV-related TB in the study setting (on
average fewer than 10 cases annually) (Study II), made it particularly challenging for care
providers to follow guidelines and recommended routines by memory. These findings,
which are consistent with the gaps in TB expertise reported by Moro et al. (2005) in Italy
(also a low-incidence setting), indicate the need for better guideline-based support.
The challenges related to insufficient knowledge about guidelines are not unique to low-
incidence settings. Two recent review studies have reported on this lack of awareness
of anti-TB treatment guidelines (van der Werf et al., 2012) and the poor guideline ad-
herence (Langendam, van der Werf, Huitric, & Manissero, 2012). Almost all continents
were represented in these studies although the first study included no European coun-
tries. van der Werf et al. (2012) found that incomplete knowledge of anti-TB treatment
regimens and anti-TB treatment duration was common. In the study setting of this the-
sis, variation in the duration of anti-TB treatment was generally longer than the guide-
lines recommended (Study II). This issue was not examined in the research for this thesis.
However, the care providers said they needed support with treatment initiation and with
monitoring routines (Study I). Langendam et al. (2012) found that because inappropriate
drug prescriptions in anti-TB treatment are common, there is a risk of resistance to drug
therapy. The authors of the study emphasize the need to improve the implementation of
treatment guidelines.
6.1.3 Information management
The National Academy of Engineering (US) and Institute of Medicine (US) Committee
on Engineering and the Health Care System (2005) emphasize the critical role of infor-
mation and communication technology (ICT) in improving the quality of patient care.
In Sweden, ICT is well integrated in the organizational development of healthcare (Min-
istry of Health and Social Affairs, 2011). In particular, Sweden is a leading country in the
development and use of quality registries (Sousa, Bazeley, Johansson, & Wijk, 2006). The
InfCare HIV quality registry, which is one of the most highly developed registries in Swe-
den, aims to provide decision support by visualizing clinical data related to antiretroviral
therapy (Rosén, 2010). At the time of this research, there was no support for HIV-related
TB treatment or guidelines that the care providers wanted (Studies I and IV). The care
providers said that the EHR system did not provide support sufficient to efficiently follow
up anti-TB treatment (Study I). This lack of support resulted in time-consuming searches
for information and a high cognitive workload for care providers.
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6.1.4 Collaboration and communication
In the studied setting, physicians and nurses collaborated in care teams, which is a rec-
ommended practice in chronic care management (Wagner, 2000). Multi-professional
care teams are associated with improved quality of HIV care although they are also as-
sociated with a decrease in physician continuity (Rodriguez, Marsden, Landon, Wilson,
& Cleary, 2008). Therefore, Rodriguez et al. (2008) emphasize the need to facilitate co-
ordination within care teams. Collaboration challenges were identified both within care
teams and between the HIV and TB clinics (Study I).
The care providers also experienced communication challenges with patients that mostly
were the result of cultural and language barriers. This problem was further complicated
by some foreign patients’ distrust of interpreters. Kulane, Ahlberg, and Berggren (2010)
relate immigrants’ fear of interpreters in the studied medical setting and their reluctance
to share information with care providers to immigration policies. Strategies are needed
to address barriers related to cultural/social stigmas, fear of sharing information, and
fear of using interpreters.
Tools to educate and engage patients in their medical treatment have been successfully
implemented in other areas of chronic care (Hvitfeldt et al., 2009). A graphic visualiza-
tion of a patient’s treatment-related data, as well as recommended treatment protocols,
may facilitate communication, although such methods do not solve problems related to
immigration policies.
6.2 DESIGN OF THE EVITMA FRAMEWORK
CDS systems for drug prescriptions usually address treatment initiation or monitoring
(Pearson et al., 2009). Such systems rarely address the entire treatment process. The
eviTMA framework covers the entire treatment process, from treatment initiation to com-
pletion. The high-level representation of drug therapy guidelines consists of three linked
components: treatment, monitoring, and assessment. This structure is intended to re-
flect generic drug therapy concepts that support the activities of collaborating care teams.
Trustworthy guidelines should “provide a clear explanation of the logical relationships
between alternative care options and health outcomes, and provide ratings of both the
quality of evidence and the strength of recommendations” (Institute of Medicine (U.S.)
Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, 2011,
p. 26). For each recommendation, a clear description of potential benefits and harms
should be provided. The eviTMA framework explicitly models the logical relationships
between drug regimens and adverse effects. The care provider can thereby receive no-
tification when an adverse effect has occurred including information on the drugs that
may have been the cause.
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6.2.1 Support for workflow, admitting flexibility
A guiding principle in the design of the eviTMA framework was to support adherence to
guideline recommendations while still allowing for flexibility in their adoption. Different
approaches have been proposed that would permit more flexible use of guidelines when
integrated in CDS systems.
Intention-based guideline formalisms (e.g., ASBRU and GASTON/GASTINE) are approaches
intended to achieve flexibility in computer-based guideline representations (Miksch,
Shahar, & Johnson, 1997; de Clercq, Blom, Hasman, & Korsten, 2000; Latoszek-Berendsen,
de Clercq, van den Herik, & Hasman, 2009). These formalisms are based on the task
network model (TNM), which means they represent guidelines as structured task se-
quences. However, different pathways to a goal are supported by specifying the inten-
tions of guideline recommendations. These are examples of active systems with a cri-
tiquing communication style (see section 1.5). Critiquing support is provided through
interpreting the intention of the physician’s actions and comparing that with the inten-
tion of the recommended care plan in the computer-interpretable guideline (CIG) model,
based on patient-specific characteristics (Latoszek-Berendsen et al., 2009; Miksch et al.,
1997).
Critiquing systems have more often been associated with success than consulting sys-
tems (Sintchenko et al., 2007). However, Bouaud et al. (2006) suggest that for complex
care, such as chronic disease management, on-demand consulting systems that allow for
flexibility are more appropriate. Séroussi, Bouaud, and Antoine (2001) propose a rigid
representation of guidelines as decision trees, which is a representation used in the On-
coDoc guiding system for breast cancer treatment. Séroussi et al. (2001) stress the physi-
cian’s autonomy in controlling the medical decision process. Each node in the decision
tree represents a decision parameter; the tree leaves represent treatment plans. Flexibil-
ity during guideline execution is achieved by allowing the user to navigate through the
decision parameters, step by step. No automated advice is provided. Hence, this is a
passive system with a consulting communication style (see section 1.5)
The eviTMA CDS prototype combines the benefits of these guideline formalisms in order
to provide both passive and active support in a consulting communication style (Stud-
ies III and IV). The user initiates the CDS functionality when drug therapy guidance is
needed. While the eviTMA CDS prototype uses a consulting style, the user is not guided
through the decision-making process step by step, which may be a hindrance to care
providers (Patkar & Fox, 2008). Rather, a combination of static and dynamic recom-
mendations is used to give the user access to all drug therapy options augmented with
patient-specific recommendations (see Figure 5.4). The static recommendations present
all the treatment options that are contained in the guideline, ordered by evidence rating
(i.e., a rigid guideline representation). The dynamic recommendations provide patient-
specific warnings for non-recommended options. Once a drug regimen has been se-
lected for the patient, the CDS system can provide active support for the assessment of
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monitoring results. The rules that trigger alerts are specific to the chosen drug regimen
and to the monitoring protocol. This procedure may reduce the risk of alert fatigue.
6.3 FORMATIVE EVALUATION OF THE EVITMA CDS PROTOTYPE
The care providers found the eviTMA concept intuitive because the treatment, monitor-
ing, and assessment activities are representative of their clinical work (Study IV). All care
providers indicated their intention to use the eviTMA CDS prototype, which was demon-
strated as a potential extension or add-on to the existing InfCare HIV quality registry.
6.3.1 Benefits of a holistic overview
Sittig et al. (2008) state that one of the greatest CDS challenges is to generate summaries of
patient data that allow care providers to make a quick and adequate evaluation of the pa-
tient’s condition. One of the main identified benefits with the eviTMA CDS prototype was
the overview provided by the graphic visualization of both patient data and drug therapy
recommendations. Forsman, Anani, Eghdam, Falkenhav, and Koch (2013) show how the
integration of information from different sources into a holistic overview can support
antibiotics decision-making in the intensive care unit. The findings in this thesis indi-
cate that this type of holistic overview is also desirable in an ambulatory setting for the
treatment of complex patient conditions. In such conditions, care providers must keep
track of many parameters. The additional guideline-based support for treatment selec-
tion and monitoring provided in the eviTMA CDS prototype may be particularly useful
for long-term planned care. The monitoring protocol, for example, provides an overview
of the treatment process and supports care planning and coordination. Martínez-García,
Moreno-Conde, Jódar-Sánchez, Leal, and Parra (2013) demonstrate how the addition of
a social network component may further support care provider collaboration and shared
decision-making in the care of patients with multiple comorbidities.
6.3.2 A support for patient engagement
Varonen, Kortteisto, Kaila, and EBMeDS Study Group (2008) identified potential facilita-
tors and barriers to the implementation of CDS systems among physicians in Finland.
They found that these physicians were worried that CDS systems may have negative ef-
fects on the physician–patient relationship. The care providers described in this thesis
thought that the eviTMA CDS prototype could enhance the relationships between care
providers and patients, especially if there were language barriers. This opinion is likely
related to their current use of the InfCare HIV quality registry in patient discussions.
Ovretveit et al. (2013) describe how the continuous development of the Swedish quality
registry for arthritis has resulted in multiple uses of the quality registry and has also en-
abled greater patient involvement in shared decision-making. Because of the integrated
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guideline support in the eviTMA CDS prototype, the care providers also discussed the po-
tential for generating drug administration and monitoring reminders for patients. Stud-
ies indicate a generally positive attitude among patients to text message reminders for
HIV or TB treatment in both high- and low-income settings (Person, Blain, Jiang, Ras-
mussen, & Stout, 2011; Albino et al., 2014). A future development with patient reminders
may be a viable strategy for enhancing patients’ adherence to HIV-related TB treatment
recommendations.
6.3.3 Concerns related to workload, autonomy, and CDS integration
Two possible implementation barriers to CDS systems are the extra workloads caused
by CDS systems and the threat to physicians’ autonomy; CDS systems should be flexible
and reliable (Varonen et al., 2008). These concerns also appeared in the evaluation of
the eviTMA CDS prototype.
The care providers were concerned about the extra workload caused by the eviTMA CDS
prototype. While the holistic overview of the prototype could increase productivity, the
interaction with the CDS prototype would require additional data entry, especially by
physicians. Therefore, the nurses were concerned that the success of a future CDS sys-
tem depended on its acceptance and use by the physicians. Kilsdonk et al. (2011) report
that physicians are more willing to use a CDS system if they think the effort to use it is
worthwhile and if they feel in control of it. On the other hand, insufficient integration
of guideline-based CDS systems with clinical workflow is a major obstacle to their use
(Maviglia et al., 2003).
The combination of static and dynamic drug therapy recommendations in the eviTMA
CDS prototype aims to respect care providers’ autonomy and to avoid errors. While the
care providers thought that these recommendations could have educational value, they
were apprehensive that their clinical judgment would be subordinated to the recommen-
dations. This situation could lead to overdependence on CDS. Because the CDS proto-
type was limited to evidence-based treatment regimens, the physicians said that com-
plex cases may not be supported. Therefore, if the CDS prototype does not fully account
for the complexity of the patient’s condition, it may not always provide proper guidance.
Awareness of such risks is vital in order to prepare for and deal with the potential unin-
tended consequences of CDS (E. M. Campbell, Sittig, Guappone, Dykstra, & Ash, 2007).
The care providers emphasized that CDS systems must be reliable and stable. Wright
and Sittig (2008) describe different architectures for integrating CDS systems with clinical
information systems. Standalone systems, which require double registration of clinical
data, can cause increased workloads and data inconsistencies between systems. Both re-
sults may jeopardize patient safety. Double registration is a current problem with Swedish
quality registries (Rosén, 2010). Furthermore, there are legal constraints on the use of
quality registry data for CDS. These are important problems that require solutions prior
to CDS system implementation in clinical practice.
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6.3.4 Knowledge management requirements
The care providers pointed to the length of time it takes experts to agree on and de-
velop new guidelines. They wondered who would take responsibility for updating and
maintaining a future CDS system based on the eviTMA framework. Kim, Makhene, Size-
more, and Hafner (2012) emphasize that clinical development and research should be
conducted in parallel so as to reduce delays in implementation. These concerns are es-
pecially important in healthcare where medical treatments develop rapidly, as is the case
in HIV-related TB treatment. As of 2010, more than twenty antiretroviral agents had been
licensed (Palmisano & Vella, 2011). Additional drugs have become available since then
(Arribas & Eron, 2013). The European Medicines Agency recently approved bedaquiline
as a new anti-TB drug (European Medicines Agency, 2014). Bedaquiline was the first
new anti-TB drug to be approved in 40 years. Today there are several drugs in late phases
of clinical development (World Health Organization, 2013a).
Ash et al. (2012) emphasize that before the implementation of CDS systems in an orga-
nization, a knowledge management program should be established for their local adap-
tation, implementation, and maintenance. Ideally, clinical knowledge management is
best conducted in multi-professional teams that use web-based tools and repositories
for collaborative knowledge development and maintenance (Sittig et al., 2010).
Patel, Allen, Arocha, and Shortliffe (1998) have shown that collaboration between clinical
experts and computer scientists results in more consistent representations of computer-
interpretable guidelines than either professional group could achieve independently. Rath-
er than translating narrative guidelines into computer-interpretable representations, Goud,
Hasman, Strijbis, and Peek (2009) propose a process of parallel guideline development
and formalization in which knowledgeable experts and appropriate tools are involved
early on. Access to domain knowledge and formal verification are also central require-
ments of the process. The Observational Health Data Sciences and Informatics (OHDSI)
collaborative recently established a workgroup for the development of a standardized
drug safety knowledge base that models and maintains the effects of medical products
(Boyce et al., 2014). An integration of such a knowledge base in the eviTMA framework
could support guideline developers as well as care providers by ensuring that the most
recent knowledge about the potential harmful effects of individual drugs are always avail-
able.
6.3.5 Potential uses of eviTMA
Ash et al. (2010) state that developers of CDS systems may have a different understand-
ing of such systems than care providers. Therefore, these authors recommend defining
CDS systems more broadly to reflect the perceptions of their users. The care providers in
this thesis envisioned a multi-functional CDS system: a decision support tool; an edu-
cational support tool (for them and the patients); a collaborative tool for care providers;
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a communication tool (e.g., for patient discussions and consultation meetings); and a
quality improvement tool. Furthermore, the care providers wanted support based on
the eviTMA framework for other patient conditions, for example, for TB mono-infection.
In short, these various uses of the eviTMA CDS prototype that the care providers describe
reflect their complex need for support tools.
6.4 METHODOLOGICAL CONSIDERATIONS
Qualitative and quantitative methods were used in combination in this thesis to gain a
deeper understanding of the studied phenomena. A purposeful sampling strategy was
used in Studies I, III, and IV of this thesis in order to involve care providers with varying
expertise and experience with HIV or TB treatment. This strategy was selected to capture
multiple views from the care providers. Neither the number of participants nor their roles
in the various research phases were specified prior to the research; thus, the design can
be said to be emergent. In the following sections, issues related to the trustworthiness of
the research and limitations of the individual studies are discussed.
6.4.1 Trustworthiness
This section discusses the trustworthiness of the research by addressing issues related to
the truth value, consistency, applicability, and neutrality of the findings (Dahlgren, Em-
melin, Winkvist, & Lindhgren, 2007). The following sub-sections address these criteria,
with references to both the quantitative and the qualitative research paradigms. Each of
these issues is introduced with a question, adapted from (Dahlgren et al., 2007, Table 1,
p. 45).
6.4.1.1 Have we really measured what we set out to measure? – the truth value issue
The aim was to identify various challenges and opportunities related to HIV-related TB
treatment (Studies I and II), and to design and formatively evaluate a CDS prototype
(Studies III and IV). Triangulation of methods was used to explore these challenges and
opportunities from different perspectives. For example, both qualitative (Study I) and
quantitative (Study II) methods were used to explore and describe challenges in the study
setting. The findings from Study II corroborated the challenges identified in Study I. The
findings from Study IV further emphasized the need to address these challenges.
Prolonged engagement, negative case analysis, and member checking are also impor-
tant for establishing truth value in qualitative research (Lincoln & Guba, 1985). These
research methods are inherent in a user-centered design approach. In this thesis, the
author’s engagement with the research setting lasted throughout the four studies. In
becoming acquainted with the setting and its culture, the author could guard against
preconceived assumptions. Rapport and trust were established with the care providers,
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some of whom were actively involved in the thesis project on several data collection oc-
casions. The design of the CDS prototype was refined iteratively as new knowledge was
acquired. This design process also enabled member checking as some of the participants
were involved in several phases of the design.
6.4.1.2 Would the findings be repeated if the research were replicated in the same
context with the same subjects? – the consistency issue
Because the researcher is the data collection instrument in qualitative research, Dahlgren
et al. (2007, p. 50) claim that the likelihood of producing the same results in repeated
data collections (i.e., reliability) is “absurd”. Knowledge is constructed in the interaction
between the researcher and the participant (Kvale & Brinkmann, 2009, p. 2). Neverthe-
less, certain research measures may support the consistency of findings. For example,
in this research, the use of interview guides ensured all topics of interest were covered
and leading questions in interviews and focus groups were avoided. Moreover, an exter-
nal researcher was involved to discuss the analysis in Study I, and three researchers were
involved in the analysis in Study IV. Triangulation of methods, which was applied to the
overall thesis design, also contributes to consistency (Patton, 2002).
6.4.1.3 How applicable are our results to other subjects and other contexts? – the
applicability issue
Qualitative research aims for generalization of research findings based on a “reasoned
judgment” about the applicability of these findings in other settings (Kvale & Brinkmann,
2009, p. 262). The reader may make this type of generalization when the findings are de-
rived from a thick description of the original research (Lincoln & Guba, 1985). In this
research, the applicability of the findings was strengthened through a clear description
of the study sample and contextual factors of the setting. Some identified challenges
are strongly and specifically linked to this research setting (e.g., collaboration patterns).
However, different identified challenges may be found in other (although similar) set-
tings.
The applicability of the eviTMA framework to clinical guidelines for chronic conditions
other than HIV-related TB disease can be assumed based on the three generic activities of
treatment, monitoring, and assessment that the framework builds on. However, further
investigation is required to test this assumption. Similarly, the applicability of the GUI
prototype to other settings requires testing and evaluation.
In Study II, the limited size of the study population, the diversity of the patient group, and
the long period of study are the principal factors that challenge the generalizability of the
findings. Due to the limited population of HIV/TB coinfected patients in the research
setting, random sampling was not feasible (or needed). Patients were selected based on
inclusion criteria, which can be compared to criterion sampling in qualitative research
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(Patton, 2002, p. 238). The primary purpose of the study was not to generalize but rather
to describe the patient population in the research setting and to identify opportunities
for CDS.
6.4.1.4 To what extent are the findings affected by personal interests and biases? - the
neutrality issue
Preconceived ideas are biased only if the researcher fails to reveal them (Malterud, 2001).
Clearly, one of the author’s preconceived ideas in this research was that CDS could ad-
dress the challenges in HIV-related TB treatment. This assumption also affected the type
of challenges in focus, namely those that refer to information processing that ICT can
support. In particular, the focus was on tasks that are cognitively challenging. However,
neutrality was achieved and maintained via the discussions and analyses by the multi-
professional research team.
6.4.2 Limitations of the four studies
6.4.2.1 Study I
Interviews were selected as the best available instruments for understanding how care
providers think and for identifying the challenges they face. The critical decision method
was selected because it aims to identify the cognitive elements in decision making (Cran-
dall et al., 2006). The author’s assumption was that the identification of cognitive ele-
ments important in care providers’ decision-making would be useful in specifying the
design requirements of a CDS prototype. The interview technique relies on the identifi-
cation of critical incidents, which are characterized by a sequence of events and by crit-
ical decisions that have occurred during a limited period of time (Crandall et al., 2006).
Time pressure usually plays an important role in these incidents – hence, the term criti-
cal.
In the conduct of the interviews, two problems were encountered: 1) Most care providers
had limited experience with HIV-related TB treatment; and 2) Critical incidents as de-
scribed above were not easily identified. Nevertheless, the resulting CDM-inspired inter-
views provided insights into the challenges care providers face in the treatment of HIV-
related TB beyond decision-making.
6.4.2.2 Study II
In epidemiological studies, there is a risk of both random errors and systematic errors
(Rothman, 2002). These possible errors are of relevance in the retrospective design in
Study II, which aimed at identifying factors associated with success in anti-TB treatment
and with adverse reactions to anti-TB treatment. Due to the limited size of the study pop-
ulation, random differences between individual cases may wrongly have strengthened
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or weakened explored associations. It is also possible that existing associations between
variables could not be detected due to lack of statistical power. Possible systematic errors
of concern in this study were information bias and confounding (Rothman, 2002).
Information bias A first step in the analysis was to classify patients into different groups
based on the data collected. For example, patients were classified in a group with adverse
reactions or in a group without adverse reactions. The occurrence of adverse reactions
was determined on the basis of physicians’ clinical documentation in medical records.
Because the physicians may have evaluated and documented these reactions differently,
it is possible some patients may have been misclassified.
Measurement instruments and techniques are likely to have improved during the years
of the study (from 1987 to 2010). Hence, variations in measurement accuracy may also
have resulted in patient misclassifications. This concern is of particular relevance for the
classification of immunosuppression (based on CD4 cell counts), which was used as a
predictor variable in the multivariate logistic regression analyses.
Confounding The two potential confounders we identified as most important – age and
gender – were controlled by multivariable analysis. Owing to the limited size of the study
population, it was not feasible to include more control variables in the analysis. For ex-
ample, the potential confounder of ethnicity was not controlled although the study pop-
ulation was a multi-ethnic group.
Hence, while the explanatory power of Study II may be weak, several of the study’s results
confirm the existence of the challenges described by the care providers: the variation in
socio-demographic background of patients, the variations in treatment duration, and
the observed frequency of adverse reactions.
6.4.2.3 Study III
A user-centered approach may involve users at the evaluation stage only or, as co-design-
ers, also in the design stage (Preece, Rogers, & Sharp, 2002). In this thesis, the users were
not co-designers although they provided feedback on the research team’s design propos-
als. While a more participatory approach may be desirable, it also requires a good deal
of time by participants. Such time commitments may be limited in health care settings
(see (Frykholm, Lantz, Groth, & Walldius, 2010; Lyng & Pedersen, 2011)).
Design sketches and class diagrams were modeled and discussed by the research team.
One-to-one discussion meetings between the author and the study participants elicited
user requirements and discussions of the desired functionalities. Involving care providers
in this way can help overcome usability concerns (Kilsdonk et al., 2013). The purpose of
the iterative design and evaluation cycles was to detect problems and to refine the design
based on the acquisition of new knowledge.
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6.4.2.4 Study IV
Some researchers have pointed to the risk of publication bias with CDS system evalua-
tions. In two review studies, CDS system success was related to the system under evalu-
ation by its developers (Garg et al., 2005; Roshanov et al., 2013). This risk may be appli-
cable in Study IV. However, as Study IV was a formative evaluation, its purpose was not
to draw conclusions about the predicted success of the system but rather to improve its
design.
The focus group is a useful research method for the evaluation of group members’ inten-
tions related to the use of a system based on low-fidelity prototypes (van Velsen et al.,
2008). The presentation of an interactive prototype allowed the researchers in this study
to discuss its predicted usefulness and issues related to its ease of use. The application
of the UTAUT as an analytical framework enabled the researchers to explore known de-
terminants of behavioral intention as well as the use of technology. According to the
UTAUT, gender, age, experience, and voluntariness of use are moderating factors that
can strengthen or weaken the influence of these determinants (Venkatesh et al., 2003).
However, moderating factors were not controlled for in the focus group evaluation; only
one participant was male, none had any experience with the system, and voluntariness
of use was not discussed. These factors were not addressed because the study was not
intended to analyze associations. The focus was on identifying the potential benefits and
concerns with the demonstrated CDS prototype.
7 CONCLUSIONS
This thesis concludes that strategic measures are needed that address some of the chal-
lenges care providers face in the treatment of HIV-related TB. The eviTMA framework
proposed in this thesis may be a viable approach for modeling evidence-based drug ther-
apy guidelines that can be integrated with the clinical workflow of care teams. The eviTMA
CDS prototype provides a holistic overview of alternative drug therapy options, their po-
tential benefits and adverse effects, and recommended monitoring routines. The proto-
type supports adherence to recommended routines and yet still allows for flexibility in
their adoption. The integration of the eviTMA CDS, with its graphic visualization of pa-
tient data in a CDS prototype, led the care providers to list multiple uses of the prototype:
as a decision support and educational support tool (for care providers and patients), as
well as a tool for communication, collaboration, and quality improvement.
Several technical, organizational, and legal issues require consideration when CDS sys-
tems are implemented and used. It is also necessary to deal with the risk of overdepen-
dence on CDS and with the care providers’ concerns about increased workloads. More-
over, a knowledge management group that includes both clinical and technical experts
should be established when a CDS system is adopted. Such a group can maintain and up-
date the system’s knowledge base with medical domain knowledge and evidence-based
guidelines.
7.1 IMPLICATIONS FOR PRACTICE
The conceptual design of the eviTMA framework was evaluated in a CDS prototype for
HIV-related TB treatment. It is recommended that healthcare organizations planning to
adopt the eviTMA framework in CDS systems for modeling evidence-based guidelines
for other chronic conditions consider the following:
• The eviTMA framework is intended for integration with an electronic health record
(EHR) system or other clinical information system that can provide access to pa-
tient data.1
• A guideline modeling expertise group should be established for CDS content de-
velopment and maintenance. The guideline modeling process includes the follow-
ing main steps: 1) selection of guidelines, 2) identification of treatment, monitor-
ing, and assessment recommendations in the guidelines, 3) translation of guide-
line recommendations to a computable format, which requires resolving any am-
biguities and vagueness in the narrative guidelines, 4) validation and verification
of the resulting guideline model, 5) implementation, maintenance, and versioning
of guideline content. The modeling process can be facilitated by linking to existing
knowledge repositories, such as drug repositories, adverse drug reaction reposito-
ries, and order set repositories.
1Legal constraints for providing patient-specific decision support require consideration.
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• The design and development of a CDS system requires the involvement of repre-
sentative users at all stages. Their needs inform the system design and establish
the criteria for its evaluation. This involvement of users may lead to early detec-
tion of usability problems and possible unintended consequences. CDS content
and functionality require proper integration in the technical, organizational, and
clinical contexts.
7.2 FUTURE RESEARCH
Future research may evaluate the usability of the eviTMA framework in a clinical set-
ting. In this effort, researchers may investigate the development of tools and strategies
that support the development, maintenance, and sharing of guideline content, as well as
the implementation and transferability of guideline-based CDS systems. As the design
of CDS systems is informed by users’ needs, implementation in different contexts may
require adaptation. Finally, the effects on practitioner performance, as well as patient
outcomes, call for additional evaluations aimed at continuous improvement.
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APPENDIX STUDY I
TASK DIAGRAM INTERVIEW GUIDE (SWEDISH)
Bakgrund 
• Hur lång erfarenhet har du inom hiv/tb-vården? 
• Hur uppskattar du din erfarenhet av att behandla patienter med dubbelinfektion (hiv och tb)? 




1. Tänk på vad du gör när du gör en behandlingsplan. Kan du beskriva vilka steg eller deluppgifter 
som ingår? Det borde helst vara mindre än 6, men mer än 3 uppgifter.  
 
• Återbesök 
1. Vilka är de övergripande målen med uppföljningsbesöken? 
2. Hur uppnås dessa mål? 
3. När och hur gör man ändringar i behandlingsplanen? 
 
• Av de steg/deluppgifter du precis har identifierat, vilka uppgifter ställer störst krav på kognitiva 
färdigheter? Med det menar jag bedömning, värdering, problemlösning, beslutsfattande. 
 
Avslutning 
• Har du något mer du vill tillägga? 
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CDM INTERVIEW GUIDE (SWEDISH)
Intro 
Hur lång erfarenhet har du inom hiv/tb vården? 
 
1 - Fall identifiering 
 
OBS! Berättelse om vad som hände och gjordes, inte förklaringar om vad och hur man bör göra.  
 
Kan du berätta om en utmanande situation du har upplevt?  
Har det hänt att du har missat/glömt något? 
Har det hänt att du har fattat ett felaktigt beslut? 
 
2 – Tidslinje 
 
Har jag förstått det här rätt? 
Var på tidslinjen ska jag sätta detta? 
Beslutspunkter, ändringar i förståelse, probing-punkter, gap i historien, glapp i tidslinjen, konceptuella 
språng, anomalier/överraskningar, fel, flertydiga ledtrådar 
 




Vad hade du för specifika mål vid det här tillfället? 
Vad var viktigast att göra vid det här tillfället? 
Vad ville du uppnå? 
Ledtrådar Vad lade du märke till? 
Hur visste du att du behövde fatta ett beslut? 
Hur visste du vad du behövde göra? 
Vad hade du för bekymmer? 
Vad ledde till ditt beslut? 
Standard 
procedurer 
Är detta ett typiskt fall? 
Finns det riktlinjer för denna typ av fall? 
Erfarenhet Vilken erfarenhet krävdes? 
Konceptuell/ 
Mental modell 
Tänkte du på möjliga konsekvenser? 
Vad för mental bild skapade du över situationen? 
Hur bedömde du situationen? 
Hur skulle du sammanfatta situationen så här långt? 
Informations-
tillgång 
Vilken information hade du? 
Hur fick du tillgång till informationen? 
Informations-
användning 
Vilken information använde du? 
Vilken information var viktigast och varför? 
Var det svårt att hantera informationsmängden? Beskriv situationen i detalj. 
Hjälpmedel/ 
Stöd 
Bad du om någons hjälp eller använde något hjälpmedel? 
Hur visste du att du kunde lita på det stöd du fick? 
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Möjligheter Fanns det några alternativ? 
Varför förkastades dessa alternativ? 
Osäkerhet Var du osäker över tillförlitligheten eller relevansen av informationen du hade till ditt förfogande? 
Var du vid något tillfälle osäker över beslutets lämplighet? 
Fel Försäkrade du dig att ditt beslut var rätt? Hur gjorde du det? 
 





Vad för misstag kan man tänka sig att en junior kliniker skulle ha gjort i en sådan situation och varför? 
Skulle en junior kliniker ha lagt märke det som du upptäckte? 
Skulle en junior kliniker ha vetat att X måste göras? 
Hypoteser Om [key feature] hade varit annorlunda, vad för inflytande skulle det ha haft på ditt 
beslut/bedömning/handlingar/plan? 
Erfarenhet Vilken typ av erfarenhet skulle ha varit en fördel i den här typen av situation? 









a. Under vilka omständigheter skulle du använda ett sådant system? 
 
• Kärnfunktioner 
a. För vilka ytterligare uppgifter/beslut behövs ett stöd? 
 
• Perifera funktioner 
a. För vilka uppgifter/funktioner behövs inget stöd? 
 
Integration i arbetsflödet 
 
• Tidpunkt för beslutsfattande 
a. När i behandlingsprocessen fattas beslut? Före/efter/under patientmöten? 
b. Hur ofta görs uppdateringar/ändringar? 
 
• Beslutsfattandeprocess 
a. Vem är involverad? 
b. Vilka resurser/hjälpmedel används? 
c. Vem måste känna till beslutet? 
d. Hur kommuniceras beslutet? 
 
• Längd på planeringen 
a. Definieras en start- och sluttid på de planer som görs? 








FOCUS GROUP TOPIC GUIDE (SWEDISH)
INTRODUKTION 
● Kort introduktion om bakgrunden till projektet och syftet med fokusgruppen 
● Carolina beskriver konceptet bakom beslutsstödet samt demonstrerar dess funktion med ett 
konstruerat patientfall 
● Tomas och Jonas startar fokusgruppsdiskussionen 




● Vilka är era spontana reaktioner när det gäller beslutstödet? Hur/varför? 
● Är det lätt eller svår att förstå? Hur/varför? 
● Är det något som fattas? Är det något som är onödigt? Hur/varför? 
 
Beslutsstödets uppdelning i behandling, monitorering och tolkning 
● Vilka är era spontana reaktioner när det gäller beslutstödets uppdelning i stöd för behandling, 
monitorering och tolkning? Hur/varför? 
● Är det lätt eller svår att förstå? Hur/varför? 
● Är det något som fattas? Är det något som är onödigt? Hur/varför? 
 
Behandlingsrekommendationer 
● Vilka är era spontana reaktioner när det gäller beslutstödets funktion för rekommendationer? 
Hur/varför? 
● Är det lätt eller svår att förstå? Hur/varför? 
● Är det något som fattas? Är det något som är onödigt? Hur/varför? 
 
Monitoreringsstöd 
● Vilka är era spontana reaktioner när det gäller beslutstödets monitoreringsprotokoll/checklista 
gällande uppfölljning under behandlingen? Hur/varför? 
● Är det lätt eller svårt att förstå? Hur/varför? 
● Är det något som fattas? Är det något som är onödigt? Hur/varför? 
 
Tolkningsstöd för biverkningar 
● Vilka är era spontana reaktioner när det gäller beslutstödets funktion för tolkning av biverkningar? 
Hur/varför? 
● Är det lätt eller svår att förstå? Hur/varför? 
● Är det något som fattas? Är det något som är onödigt? Hur/varför?  
 
Varningar och åtgärder 
● Vilka är era spontana reaktioner när det gäller beslutstödets funktion att förmedla varningar och 
rekommendera åtgärder? Hur/varför? 
● Är det lätt eller svår att förstå? Hur/varför? 
● Är det något som fattas? Är det något som är onödigt? Hur/varför? 
 
ANVÄNDBARHET 
● Används rätt termer och begrepp? Hur/varför? 
● Verkar beslutstödets enkelt att använda? Hur/varför? 
● Verkar det finnas tillräckligt många olika sätt att göra det ni vill med beslutstödet för att ni ska kunna 
anpassa den till just ert sätt att använda det? Hur/varför? 
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INFLYTANDE PÅ ARBETSRUTINER 
● Skulle beslutstödet påverka ert sätt att arbeta, före, under och/eller efter ett patientbesök? Hur/varför? 
● Tror ni att beslutstödet skulle användas i samtalet med patienten, som ett slags samtalsstöd? 
Hur/varför? 
● På vilket sätt skulle beslutstödet påverka samarbete och samordning av vård? Hur/varför? 
● Hur ofta och i vilka situationer skulle ni använda beslutstödet (enskilt, i vårdteam, i 
vårdsammansträden)? I vilka inte? Hur/varför? 
  
ACCEPTANS 
● Vilka nackdelar/fördelar ser ni med att använda använda beslutsstödet?? Hur/varför? 
● Vilka hinder kan ni se att det finns för att ni ska använda beslutsstödet? Hur/varför? 
● Tror ni att beslutsstödet underlättar tillämpningen av evidensbaserade riktlinjer? Hur/varför? 
● Tror ni att beslutsstödet underlättar uppföljningen efter behandlingsstart? Hur/varför? 
● Är det en bra idé att använda beslutsstödet för tillämpning av kliniska riktlinjer? Hur/varför? 





CDS PROTOTYPE SCREEN PRINTS (SWEDISH)












Figur  4.  Tolkningsstöd  för  biverkningar
4a 4b
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Figur  5.  Varningar  och  åtgärder
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